IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 4 of 95 TABLE OF CONTENTS 
KEY STUDY ROLES ............................................................................................................... ......2 
TABLE OF CONTENTS ............................................................................................................. ....4 
SPONSOR SIGNATURE ............................................................................................................. .11 
INVESTIGATORâ€™S SIGNATURE ............................................................................................... [ADDRESS_1222784] OF ABBREVIATIONS AND DEFINITIONS OF TERMS ................................................ 13 
SYNOPSIS ...................................................................................................................... ............... 16 
ELIGIBILITY CRITERIA........................................................................................................... ..19 
INCLUSION CRITERIA......................................................................................................... 19 
EXCLUSION CRITERIA ....................................................................................................... 21 
SCHEDULE OF EVENTS ............................................................................................................ 24 
1. INTRODUCTION ................................................................................................................. 27 
1.1 HEART FAILURE WITH PRESERVED EJECTION FRACTION .......................... 27 
1.2 PATHOPHYSIOLOGY OF HFPEF............................................................................ 27 
1.3 RATIONALE FOR USE OF AN SGC STIMULATOR IN HFPEF ........................... 28 
1.3.1  IW-1973 ............................................................................................................. 29 
[IP_ADDRESS]  Nonclinical Data in Support of Clinical HFpEF Investigations .............. 29 
2. STUDY OBJECTIVES .......................................................................................................... 30 
3. INVESTIGATIONAL PLAN ................................................................................................ 31 
3.1 OVERALL STUDY DESIGN AND PLAN ................................................................ 31 
3.2 DISCUSSION OF STUDY DESIGN AND CONTROL GROUP .............................. 33 
3.3 STUDY DURATION .................................................................................................. 34 
3.4 STUDY POPULATION .............................................................................................. 34 
3.4.1  Removal of Patients from Therapy or Assessment ............................................ 34 
3.4.2  Early Termination Procedures ........................................................................... 35 
3.5 STUDY TREATMENT(S) .......................................................................................... 36 
3.5.1  Description of Treatment(s) ............................................................................... 36 
[IP_ADDRESS]  Investigational Product ............................................................................ 36 
[IP_ADDRESS]  Placebo ..................................................................................................... 36 
[IP_ADDRESS]  Packaging and Labeling ........................................................................... 36 
[IP_ADDRESS]  Dosage...................................................................................................... 36 
[IP_ADDRESS]  Storage and Accountability ...................................................................... 37 
3.5.2  Method of Assigning Patien ts to Treatment Groups.......................................... 38 
3.5.3  Selection of Dosage in the Study ....................................................................... 38 
3.5.4  Selection and Timing of Dose for Each Patient and Dose Reduction ............... 39 
[IP_ADDRESS]  Study Drug Administration ...................................................................... 39 
[IP_ADDRESS]  Dose Reduction ........................................................................................ 39 
3.5.5  Treatment Compliance ....................................................................................... 40 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 6 of 95 [IP_ADDRESS]  Causality Assessment............................................................................... 52 
[IP_ADDRESS]  Severity Assessment ................................................................................ 53 
[IP_ADDRESS]  Serious Adverse Events ........................................................................... 53 
[IP_ADDRESS]  Recording Adverse Events ....................................................................... 54 
[IP_ADDRESS]  Reporting Serious Adverse Events .......................................................... 55 
3.8.14  Cardiac Events ................................................................................................... 56 
3.8.15  Pharmacokinetic Assessments ........................................................................... 56 
3.8.16  Genotypi[INVESTIGATOR_007] (Optional, pe r Patient Consent) ...................................................... 56 
4. STUDY ENDPOINTS ........................................................................................................... 57 
4.1 PRIMARY ENDPOINTS ............................................................................................ 57 
4.1.1  Primary Safety ................................................................................................... 57 
4.1.2  Primary Efficacy ................................................................................................ 57 
4.2 SECONDARY ENDPOINTS ...................................................................................... 57 
4.2.1  Secondary Efficacy ............................................................................................ 57 
4.3 EXPLORATORY ENDPOINTS ................................................................................. 57 
  
  
  
  
  
  
  
  
  
  
5. STATISTICAL METHODS .................................................................................................. 60 
5.1 GENERAL CONSIDERATIONS ............................................................................... 60 
5.1.1  Continuous Endpoints ........................................................................................ 60 
5.1.2  Responder Endpoints ......................................................................................... 60 
5.2 DETERMINATION OF SAMPLE SIZE .................................................................... 61 
5.3 ANALYSIS POPULATIONS ..................................................................................... 62 
5.4 PATIENT DISPOSITION ........................................................................................... 62 
5.5 DEMOGRAPHICS AND BASELINE CHARACTERISTICS .................................. 62 
5.6 DRUG EXPOSURE AND COMPLIANCE ................................................................ 62 
5.7 PRIOR AND CONCOMITANT MEDICATIONS AND PROCEDURES ................ 63 
5.8 MAJOR PROTOCOL DEVIATIONS ......................................................................... 63 
5.9 EFFICACY ANALYSES ............................................................................................ 63 
5.9.1  Controlling for Multiplicity ............................................................................... 63 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222785] OF IN-TEXT TABLES 
Table 1.  Key Study Participants ......................................................................................... 2 
Table 2.  External Data Evaluation Bodies and Study Committees ................................... 3 
Table 3.  Dose Regimen by [CONTACT_875531] ........................................................ 36 
Table 4.  Dose Regimen by [CONTACT_875531] ........................................................ 37 
Table 5.  Categories of SAEs Triggering Individual Stoppi[INVESTIGATOR_875509] ............................................................................................................... 43 
Table 6.  [LOCATION_001] Heart Association ( NYHA) Functional Classification ..................... 47 
Table 7.  Clinical Laboratory Tests ................................................................................... 48 
 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222786] OF IN-TEXT FIGURES 
Figure 1.  Study Schematic ................................................................................................ 31 
 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222787] OF APPENDICES 
Appendix 1  Prohibited Medicines and Supplements ............................................................. 82 
Appendix 2  Kansas City Cardiomyopathy Questionnaire (KCCQ) ...................................... 83 
Appendix 3  Sheehan Disability Scale (SDS) ........................................................................ 87 
Appendix 4  EuroQOL 5-dimension Questionnaire (EQ-5D-5L) .......................................... 89 
Appendix 5  Quick Inventory of Depressive Symp tomatology Self-Report (QIDS-SR-
16) ...................................................................................................................... [ADDRESS_1222788] Method .............................................................................. 94 
 
 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 12 of 95 INVESTIGATORâ€™S SIGNATURE 
[CONTACT_2759]: A Multicenter, Randomized, Double- blind, Placebo-controlled, Phase 
2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 over 12 Weeks in Patients with Heart Failure with Preserved 
Ejection Fraction (CAPACITY HFpEF) 
Study Number: C1973-204 
Final Date: [ADDRESS_1222789] the study as described in the protocol.  
 
 Signed:   Date:   
  
P r i n t  N a m e :             
 
 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222790] 
ACE angiotensin-converting enzyme 
AE adverse event 
ANCOVA analysis of covariance  
ARB angiotensin receptor blocker 
AUC area under the curve 
BID twice daily (2Ã—/day) 
BMI body mass index (kg/m2) 
BP blood pressure 
CBC complete blood count 
CDF cumulative distribution function 
cGMP cyclic guanosine 3â€™,5â€™-monophosphate 
CKD-EPI [INVESTIGATOR_875510]-Mantel-Haenszel 
CPET cardiopulmonary exercise test  
CYP3A cytochrome P450 3A 
DMC Data Monitoring Committee 
DSS Dahl salt-sensitive 
ECG electrocardiogram 
eCRF electronic case report form 
EDC electronic data capture 
E/eâ€™ ratio  mitral peak velocity [E]/mitral annulus early diastolic recoil velocity [eâ€™] 
EF ejection fraction 
eGFR estimated glomerular f iltration rate (mg/mL/1.73 m2) 
EIU exposure in utero 
FDA Food and Drug Administration 
GCP good clinical practice 
h hour(s) 
HFpEF heart failure with preserved ejection fraction  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222791] 
ITT intent to treat 
IUD intrauterine device 
IV intravenous 
IWRS interactive web response system 
  
kg kilogram 
kg/m2 kilograms/meters squared (body mass index) 
LA left atrial 
LSM least-squares mean 
LV left ventricular 
LVEDP left ventricular end-diastolic pressure 
LVEDV left ventricular end-diastolic volume  
LVESV left ventricular end-systolic volume  
m minute  
mITT modified intent to treat 
MAD multiple ascending dose 
MedDRA Medical Dictionary for Regulatory Activities 
mg milligram 
MI myocardial infarction 
mL milliliter 
mmHg millimeters of mercury 
MPV mean platelet volume 
MRA mineralocorticoid receptor antagonists  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 15 of 95 Abbreviation Term 
NO nitric oxide 
NT-proBNP N-terminal pro B-type natriuretic peptide  
NYHA [LOCATION_001] Heart Association  
pd postdose 
PDE phosphodiesterase 
PK pharmacokinetic(s) 
PT preferred term 
QD once daily (1Ã—/day) 
  
QOL quality of life 
RBC red blood cell 
RDW red blood cell distribution width 
RER respi[INVESTIGATOR_875511]-emergent adverse event 
UACR urine albumin creatinine ratio 
UGT uridine diphosphateâ€“glucuronosyl transferase 
ULN upper limit of normal 
US [LOCATION_002] 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222792] IW-1973 Tablet (praliciguat) 
Name [CONTACT_875566]-[ADDRESS_1222793] bo-controlled, Phase 2 Study Evaluating the 
Safety and Efficacy of Different Doses of IW- 1973 over 12 Weeks in Patie nts with Heart Failure 
with Preserved Ejection Fraction (CAPACITY HFpEF) 
Study Number 
C1973-204 
Study Phase:  2 
Study Objectives 
Primary  
â€¢ To assess the safety of oral IW-1973 when administered for approximately 12 weeks to 
patients with heart failure with preserved ejection fraction (HFpEF) 
â€¢ To evaluate effect of oral IW-1973 on peak exercise capacity when administered for 
approximately 12 weeks to patient s with HFpEF, both in all pa tients and in patients without 
permanent or persistent atrial fibrillation  
Secondary  
â€¢ To evaluate the effect of oral IW-1973 on exercise and functional capacity when 
administered for approximately 12 weeks to patients with HFpEF  
Study Design 
This Phase 2, multicenter, randomized, double- blind, placebo-controlled, parallel-group study 
will evaluate the safety and efficacy of IW -1973 compared with placebo when administered 
daily for approximately 12 weeks (2 weeks of twice-daily [BID] dosing followed by 10 weeks of 
once-daily [QD] dosing) in the indicated patient population. 
At the Day 1 Visit, eligible patients will be stratified by [CONTACT_875532] 2 RUÂ•RIDJH - and sex-adjusted normal va lues and with respi[INVESTIGATOR_696] 
H[FKDQJHUDWLR>5(5@Â•DVGH WHUPLQHGE\FDUGLRSXOPRQDU\H[HU FLVHWHVW>&3(7@ . Patients 
will be randomized in a 1:1 ratio to  daily 40 mg IW-1973 or placebo (see Study Treatment  
below). All patients will receive their first morn ing BID dose in the clinic on Day [ADDRESS_1222794] QD dose at the Week 2 Visit (Day 15 [Â±3]); for these [ADDRESS_1222795] stay in the 
clinic for approximately  4 hours postdose and will be released  at the Investigatorâ€™s discretion 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 17 of 95 after undergoing safety, efficacy, and pha rmacokinetic (PK) assessments per the Schedule of 
Events . At the Week 4, Week 8, and End of Treatment  visits, patients will again return to the 
clinic for study drug administration; for safety , efficacy, and PK assessments; and to receive 
additional study drug and other supplies, as applicable. Patients will return to the clinic 28 days (Day 113 Â±7) after their last study drug dose for the final Follow-up Visit. 
Study Treatment 
Patients will receive study drug for up to 89 days.  For patients randomized via Protoc ol Amendment 2 (or earlier):  On Day 1, patients will be 
randomized in a 1:1:1:1 ratio to the following 4 regimens: 
Dose Weeks 1 and 2, BID Dosing  Weeks 3 through 12, QD Dosing 
10 mg one 5-mg IW-1973 Tablet, orally twice daily two 5-mg IW-1973 Tablets, orally once daily 
20 mg one 10-mg IW-1973 Tablet, orally twice daily two 10-mg IW-1973 Tablets, orally once daily 
40 mg one 20-mg IW-1973 Tablet, orally twice daily two 20-mg IW-1973 Tablets, orally once daily 
Placebo one matching placebo tablet, orally twice dail y two matching placebo tablets, orally once daily 
BID=twice daily; QD=once daily 
 
For patients randomized starting with Amendment 3 to the protocol:  Patients will be randomized 
on Day 1 in a 1:1 ratio to the following 2 regimens: 
Dose Weeks 1 and 2, BID Dosing  Weeks 3 through 12, QD Dosing 
40 mg one 20-mg IW-1973 Tablet, orally twice daily two 20-mg IW-1973 Tablets, orally once daily 
Placebo one matching placebo tablet, orally twice dail y two matching placebo tablets, orally once daily 
BID=twice daily; QD=once daily 
 
Study Population and Planned Number of Patients 
The study will enroll approximately 184 adult patie nts with established heart failure  and limited 
exercise capacity with ejection fraction of at leas t 40% and who have at least 2 of 4 risk factors 
for HFpEF (diabetes/prediabetes, hypertension, obesity, advanced age >Â•\HDUV@7KHQXPEHU
of patients admitted with permanent or persistent atrial fibrillation will be limited to approximately 36 in the study. 
See Eligibility Criteria  for full inclusion and exclusion criteria. 
Study Assessments 
Safety : Medical history, prior and concomitant medications and surgeries/procedures, and 
adverse events will be collected. Physical examination, vital sign measurements including orthostatic blood pressure, clinical  laboratory tests, pregnancy te sts, and electrocardiograms will 
be performed. 
Efficacy : CPET, 6-minute walk tests (6MWT), and echocardiography will be performed. New 
York Heart Association (NYHA) functional classi fication will be deter mined. Cardiac events 
will be analyzed. Blood and urine will be co llected for biomarke r determinations.  
Patient-reported outcomes : Patients will self-ad minister the following questionnaires: Kansas 
City Cardiomyopathy Questionnaire (KCCQ), Sh eehan Disability Scale (SDS), EuroQol-5D-5L 
(EQ-5D-5L), and Quick Inventory of De pressive Symptomatology (QIDS)-SR-16. 
Pharmacokinetics : Blood will be collected to determine plasma concentrations of IW-1973. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 18 of 95 Dose Reduction, Individual Stoppi[INVESTIGATOR_2121], and Data Monitoring Committee (DMC) 
Per Investigator discretion, a dose reduction for an individual patient is allowed after 
consultation with the Medical Monitor. If approved, the patient will reduce his or her daily dose by [CONTACT_2016], ie, from 2 to 1 tablet daily. It is re commended that the patient to be evaluated in the 
clinic in association with any dose modificati on. Each patientâ€™s dose may only be reduced once 
and will not be increased after reduction. 
Also on an individual basis, a patient will be discontinued from study drug dosing if any of the 
following are reported: a study drug-related serious adverse event (SAE) of spontaneous 
bleeding; a life-threatening symptomatic hypotension-related SAE; or [ADDRESS_1222796] patient is randomized.  
Statistical Methods 
There will be no statistical adjustment for multiple testing. All reported p-values will be 
considered nominal. Ninety-two patients per arm will provide approximately 90% power to detect a clinically meaningf ul difference between the 40-mg IW-1973 treatment arm and the 
placebo treatment arm in change from baseline at Week 12 peak VO
2 in all patients and/or in 
patients without permanent or pe rsistent atrial fibrillation.  
Final Date:  27 June 2018 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222797] meet all of the following criteria to be eligible for enrollment in this study: 
1. Patient has signed an informed consent form (I CF) before any study-specific procedures are 
performed. 
2. 3DWLHQWLVDQDPEXODW RU\PDOHRUIHPDOHÂ• 45 years old at the Screening Visit. 
3. Patient has heart failure with  ejection fraction (EF) of Â•0% as assessed within 12 months of 
the Screening Visit, without previously doc umented EF of <40%. (If echocardiography 
results are not documented in th e patientâ€™s medical history, the Investigator may perform an 
echocardiography at the Screening Visit.) Eligibility will be based on Investigator analysis. 
4. Patient has a peak VO 2 measuring <80% of age- and sex- adjusted normal (see table) and a 
UHVSLUDWRU\H[FKDQJHUDWLR5(5Â• at the Baseline Visit cardiopulmonary exercise test 
(CPET) as determined by [CONTACT_493217].  
 
Age- and Sex-adjusted Normal Peak VO 2 
Age (years) Sex Normal Peak VO 2  
(mL O 2/kg/min) 80% of Normal Peak VO 2 
(mL O 2/kg/min) 
50-59 M 36 28.8 
50-59 F 29 23.2 
60-69 M 33 26.4 
60-69 F 27 21.6 
>70 M 29 23.2 
>70 F 27 21.6 
Source: Fletcher et al, 1995 ( 1) 
F=female; M=male  
 
5. Patient may have permanent or persistent atrial fibrillation; total number of patients with 
permanent or persistent atrial fibrillation will be limited to approximately 36. (Note: Patients with intermittent [paroxysmal] atrial fibrillation must be in normal sinus rhythm at the time of the baseline CPET; these patients will not count toward the limit of 36 patients with 
permanent or persistent atrial fibrillation.) 
6. Patient has evidence in medical history supportin g clinical heart failure  syndrome consisting 
of at least 1 of the following: 
a. Hospi[INVESTIGATOR_875512], with 
at least 2 of the following documented:   
o Volume overload on presentation as eviden ced by [CONTACT_2669] 2 of the following 
5 signs: jugular venous distension, pi[INVESTIGATOR_13034] Â•1+, ascites, pulmonary 
congestion on chest x-ray, or pulmonary rales  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 20 of 95 o B-type natriuretic peptide (BNP) Â•>VLQXV[LOCATION_006]\WKP@Â• 200 pg/mL [atrial 
fibrillation]) or N-termin al pro BNP (NT-proBNP) (>300 [sinus rhythm] or 
Â•600 pg/mL [atrial fibrillation])  
o Treatment with intravenous (IV) diuretics with clinical response  
b. %13Â•>VLQXV[LOCATION_006]\WKP@Â• pg/mL [atrial fibrillation]) or NT-proBNP (>300 [sinus 
rhythm], >600 pg/mL [atrial fibrillation]) within the past 6 months. (If needed for eligibility, a sample for NT-proBNP level may be collected at the Screening Visit.) 
c. Echocardiographic evidence within the past [ADDRESS_1222798] 2 of the following: left 
ventricular (LV) hypertrophy, left atrial (LA) enlargement, or diastolic dysfunction 
PHGLDO(H
UDWLRÂ• 15)  
d. Hemodynamic evidence of elevated filling pressures, as indicated by [CONTACT_875533][INVESTIGATOR_171438] Â•[ADDRESS_1222799] or >[ADDRESS_1222800] 12 months, 
or left ventricular e nd-diastolic pressure Â•15 mmHg 
7. Patient has [LOCATION_001] Heart Association (NYHA) Class II-IV symptomatology as assessed at 
the time of the Screening Visit. The classifications are described in Section 3.8.7 (Table 6 ). 
8. Patient is on stable dose(s) of any current cardiovascular medication (eg, angiotensin-
converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], beta-blockers, mineralocorticoid receptor antagonists [MRAs]) for at least [ADDRESS_1222801] 2 of the following criteria at the Screening Visit:  
a. Diagnosis of type 2 diabetes mellitus or prediabetes (currently treated or hemoglobin A1c 
Â•  
b. History of hypertension (on at l east 1 antihypertensive medication or has current seated 
blood pressure [BP] >140/90 mmHg) 
c. Body mass index (BMI) >30 kg/m2 
d. $JHÂ•\HDUV  
10. Female patient must  be postmenopausal QRPHQVHVIRUÂ•FRQVHFXWLYHPRQWKV  or 
surgically sterile (ie, bilateral oophorectomy, hy sterectomy, or tubal st erilization [tie, clip, 
band, or burn]). Female patients of reproductive potential must agree to completely abstain 
from heterosexual intercourse; or, if heterosexually active, must agree to use 1 of the following methods of birth control from the da te she signs the ICF until 60 days after the 
final dose of study drug: 
a. Progesterone implant and/or an intrauterine device (IUD), or 
b. Combination of 2 highly effective birth cont rol methods (eg, diaphragm with spermicide 
plus a condom, condom with spermicide plus  a diaphragm or cervical cap, hormonal 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 21 of 95 contraceptive [eg, oral and transdermal patc h] combined with a barrier method, partner 
wLWKYDVHFWRP\>FRQGXFWHGÂ•GD\VEH IRUHWKH6FUHHQLQJ9LVLWRU FRQILUPHGYLDVSHUP
analysis] plus a hormone or barrier method).   
11. Male patients who are not VXUJLFDOO\VWHULOHE\YDVHFWRP\FRQGXFWHGÂ•  days before the 
Screening Visit or confirmed via sperm analysis) must agree to completely abstain from heterosexual intercourse or, if  heterosexually active, must agree to use a highly effective 
birth control method (eg, condom with spermic ide; partner IUD; partner diaphragm or 
cervical cap; partner hormonal contraceptive [including progesterone implant]; or 
postmenopausal partner [ QRPHQVHVIRUÂ•FRQVHFXWLYHPRQWKV ]) starting from the 
Screening Visit through [ADDRESS_1222802] agree not to make any major lifes tyle (eg, diet, exercise) changes from the 
Screening Visit through the Follow-up Visit. 
EXCLUSION CRITERIA 
Patients who meet any of the following criteria will not be eligible to participate in the study:  
1. Patient has had acute coronary  syndrome or percutaneous coronary intervention within 
30 days before Randomization. 
2. Patient has had cardiac transp lantation or has cardiac tran splantation planned during the 
study. 
3. Patient has had coronary artery by[CONTACT_804956] t, cardiac mechanical support implantation, or 
other cardiac surgery in the 3 months before th e Screening Visit or planned during the study. 
4. Patient has severe chronic obs tructive pulmonary disease (COP D) as defined by [CONTACT_875534]. Nighttime oxygen is not exclusionary. 
5. Patient had had heart failure hospi[INVESTIGATOR_875513] 30 days before the 
Baseline Visit. 
6. Patient has hypertrophic cardiomyopathy ( obstructive or nonobstructive), restrictive 
cardiomyopathy, active myocarditis, constric tive pericarditis, cardiac sarcoidosis, or known 
amyloid cardiomyopathy. 
7. Patient has uncontrolled arrhythmias other than permanent or persistent atrial fibrillation. 
8. Patient has history of uncorrected congen ital cardiac disease affecting LV function. 
9. Patient has evidence of severe chronotropic in competence, as indicat ed by a heart rate 
response <55% of predicted maximum heart rate (220 â€“ age) per Baseline Visit CPET. 
10. Patient has any history of platelet dy sfunction, hemophilia, von Willebrand disease, 
coagulation disorder causing a bl eeding diathesis, other bleedin g diathesis, or significant, 
nontraumatic bleeding epi[INVESTIGATOR_1841], such as from a gastrointestinal source. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 22 of 95 11. Patient has uncorrected thyroid disease. 
12. Patient has severe aortic stenosis or severe mitral regurgitation. 
13. Patient has seated systolic BP <110 mmHg at  the Screening Visit and on Day 1 before 
Randomization. For these deter minations of eligibility, BP will be the average of 
3 measurements obtained at approximately 2- minute intervals after the patient has been 
VLWWLQJTXLHWO\IRUÂ•  minutes. 
14. Patient has estimated glom erular filtration rate  (eGFR) <30 mL/min/1.73m2 at the Screening 
Visit and/or is receiving dialysis. 
15. Patient has direct bilirubin >2  times upper limit of norma l (Ã—ULN, as defined by [CONTACT_13754]) 
or alanine aminotransferase (ALT) or aspart ate aminotransferase (AST) >3Ã—ULN at the 
Screening Visit.  
16. Patient has received IV inotropic therapy w ithin 30 days before the Screening Visit. 
17. Patient is unable to ta ke oral medications. 
18. Patient has active or treated malignancies within 12 months of the Screening Visit, except for 
basal cell carcinoma. 
19. Patient has previously receive d IW-1973, has received any othe r investigational drug during 
the 30 days or 5 half-lives of that investiga tional drug (whichever is longer) before the 
Screening Visit, is planning to receive another investigational drug at any time during the study, has an active investigati onal medical device currently impla nted, and/or is planning to 
have an investigational medical device implanted at any time during the study. 
20. Patient has comorbid condition with an expected survival less than 6 months. 
21. Patient has any medical condition that, in the I nvestigatorâ€™s opi[INVESTIGATOR_1649], could lead to difficulty 
complying with protocol procedures (eg, 6-minute walk test, CPET) or could prohibit 
completion of the study. Specifically, patients should not be primarily limited in their physical activity by [CONTACT_467580], leg, hip or back pain, or gait unsteadiness. 
22. Patient has evidence of active hepatitis or human immunodeficiency virus antibody at the 
Screening Visit. 
23. Patient has clinically significan t (per Investigator judgment) history of viral or bacterial 
infection within [ADDRESS_1222803] ug addiction during the 12 months before the 
Screening Visit and/or has a positive drug screen at the Screening Visit for amphetamines, barbiturates, benzodiazepi[INVESTIGATOR_1651], cocaine, opi[INVESTIGATOR_375789], phencyclidine, propoxyphene without a 
prescription for a medically defined condition. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 23 of 95 26. Patient is taking specific inhibitors of phosphodi esterase 5 (PDE5), nonspecific inhibitors of 
PDE5 (including dipyridamole and theophy lline), any supplements for the treatment of 
erectile dysfunction, riociguat, a nd/or nitrates or nitric oxide (NO) donors in any form. These 
medications and supplements are prohibited fro m 7 days before Randomization through the 
duration of the study. 
Patient is taking strong cytochrome P450 3A (CYP3A) inhibitors, exam ples of which include 
azole antifungals, macrolide antibiotics, pr otease inhibitors, and diltiazem. These 
medications and excessive grap efruit intake are prohibited [ADDRESS_1222804] of prohi bited medicines and supplements. 
27. Patient has a history of clinically significant hypersensitivity or allergy to any of the 
ingredients contained in the active or placebo drug products. 
28. Female patient is pregnant (positive urine pregnancy test) or is breastfeeding. Breastfeeding 
is not allowed from Screening Visit through 60 days after the final dose of study drug.  
29. Female patient who may wish to become preg nant and/or plans to undergo egg donation or 
egg harvesting for current or future in vitro fertilization during the study and/or within at least [ADDRESS_1222805] 
60 days after the final dose of study drug. 
31. Patient will not be able to adhere to the trial assessment schedule or, in the clinical judgment 
of the Investigator, is otherwise not suitable for the trial. 
 
NOTES :  
â€¢ Patients may be rescreened should they discon tinue in the Screening Period due to visit 
window deviations or other administrative reasons.  
â€¢ Laboratory values or BPs that are outside the ra nge specified in the protocol may be repeated 
to confirm eligibility during the Screening Period at the Investigatorâ€™s discretion after consultation with the Medical Monitor. 
â€¢ The Screening and Baseline Visits can be comb ined if the visit occurs within [ADDRESS_1222806]]DWLRQDQGWKHSDWLH QWKDVIDVWHGIRUÂ•  hours.  
â€¢ With prior approval by [CONTACT_1689],  local laboratory results may be used to 
determine study eligibility. In this instance, SDWLHQWVPXVWKDYH IDVWHGIRUÂ•  hours prior to 
collection of the laboratory samples and duplicate samples must be drawnâ€”1 set will be used for determination of study eligibility by [CONTACT_875535]. The Randomization Visit can then occur on the next day. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 24 of 95 SCHEDULE OF EVENTS 
 
Visit Days Äº 
Study Procedure Ä» Screening Period Treatm ent Period FU Period  
Screening 
Visit* (Day -
45 to -3) Baseline *Visit 
(Day -14 
to -3) Randomization 
Visit (Day 1) Week 2 Visit 
(Day 15 Â±3) Week 4 Visit 
(Day 29 Â±3) Week 8 
Visit  
(Day 57 Â±3) Week 12/ EOT 
Visit (Day 85 -
7/+4) FU Visit  
(Day 113 Â±7) 
ICF signed X        
Demographics X        
Medical history X        
Inclusion/exclusion X X X      
Prior & concomitant 
medications and 
procedures X X X X X X X X 
Physical exam ( a) complete pre CPET predose  predose  predose  predose  predose  complete 
Vital signs (BP, pulse, 
RR, & oral temperature) 
(b) X pre CPET SUHÂ”K  
pd: 1,3,4h 
(Â±20m) SUHÂ”K  
pd: 1,3,4h 
(Â±20m) SUHÂ”K  SUHÂ”K  SUHÂ”K  X 
Weight, height W, H W W W W W W W 
NYHA classification X  X    X X 
Hepatitis, HIV screen X        
Urine drug screen  X        
Urine pregnancy ( c) X pre CPET predose predose predose predose predose X 
Urinalysis sample ( d) X  predose predose predose predose predose X 
Serum chemistry, CBC, 
coagulation ( d) X pre CPET  predose predose predose predose  predose X 
Hemoglobin A1c X pre CPET    predose predose X 
12-lead ECG ( e) X pre CPET predose predose predose predose predose  
Adverse events X X X X X X X X 
CPET ( f) 
 X    postdose 
>1h (or 
Â±3 days) ( f) postdose >1h  
6MWT ( g)  post CPET 
>1h     post CPET 
>1h ( g) post CPET >1h  
NT-proBNP sample ( d,h) X (if needed) pre CPET     predose  
Echocardiography ( i) X (if needed) X (for baseline)    X  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 25 of 95  
Visit Days Äº 
Study Procedure Ä» Screening Period Treatm ent Period FU Period  
Screening 
Visit* (Day -
45 to -3) Baseline *Visit 
(Day -14 
to -3) Randomization 
Visit (Day 1) Week 2 Visit 
(Day 15 Â±3) Week 4 Visit 
(Day 29 Â±3) Week 8 
Visit  
(Day 57 Â±3) Week 12/ EOT 
Visit (Day 85 -
7/+4) FU Visit  
(Day 113 Â±7) 
Fasting plasma glucose & 
insulin ( d)  pre CPET  predose   predose predose X 
UACR sample supplies 
dispensed  X    X   
First-void urine samples 
(j)   preVisit    preVisit  
Pharmacokinetic blood 
samples   predose 
pd:1,2,4h 
(Â±20m) predose 
pd:1,2,4h 
(Â±20m) predose predose predose 
pd:1,2,4h 
(Â±20m) X 
Orthostatic (sitting to 
standing) pulse, BP ( k)   SUHÂ”K  
pd: 2,4h (Â±20m) SUHÂ”K  
pd: 2,4h 
(Â±20m)   SUHÂ”K   
Randomization   X      
Study drug dispensed   X X X X   
In-clinic study drug ( l)   X X X X X  
Study drug return    X X X X  
Study completion        X 
 
 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 27 of 95 1. INTRODUCTION 
1.1 HEART FAILURE WITH PRESERVED EJECTION FRACTION 
Heart failure with preserved ejection fraction (HFpEF) is a significant source of morbidity and 
mortality in the [LOCATION_002] (US) and globally.( 2, 3) It currently comprises approximately 50% 
of new heart failure diagnoses in the US, and the prevalence is estimated to be at least 1% of the 
population, or more than 3 million Americans.( 2, 4) Patients with HFpEF account for 
approximately half of hospi[INVESTIGATOR_875514]-admitted following 
discharge.( 5) Mortality rates over [ADDRESS_1222807] been reported 
to range from 55% to 74%.( 6) Patients with HFpEF have the signs and symptoms of heart 
failure, which may include dyspnea, orthopnea, lower extremity edema, pulmonary congestion, 
and cardiomegaly; tend to have low activity le vels and a suboptimal qualit y of life (QOL); and 
frequently experience depression.( 7) Although there are approved treatments for heart failure 
with reduced ejection fraction (HFrEF) that re duce death and hospi[INVESTIGATOR_19934], 
currently there are no approved chronic medications  specifically for HFpEF. Given the lack of 
approved therapi[INVESTIGATOR_014], there is significant unmet medical need for the large population of HFpEF 
patients. 
1.[ADDRESS_1222808] been proposed to contribute to HFpEF. Mi crovascular inflammation has been hypothesized 
to play an important role in HFpEF pathophysiology.( 8) HFpEF patients often have comorbid 
obesity and diabetes mellitus, which may contribute to a systemic inflammatory state. 
Microvascular inflammation is associated with reduced nitric oxide (NO) bioavailability that in 
turn results in reduced production of cyclic guanosine 3â€™,5â€™-monophosphate (cGMP) by [CONTACT_875536] (sGC).( 9) Decreased cGMP levels result in  impaired activation of protein 
kinase G with multiple resultant  effects, including impaired phosphorylation of titin, leading to 
increased myocardial compliance and increased synthesis of collagen.( 10) This cascade of 
effects, stemming from reduced NO bioavailability, may be important in the reduced ventricular 
compliance and myocardial remodeling that is sometimes seen in HFpEF.  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 28 of 95 Other mechanisms of derangement in NO-sGC-cGMP signaling may also contribute to the 
pathophysiology. For example, endothelial dysfunc tion can result in vascular stiffness and an 
inability to properly regulate vascular flow to skeletal muscle, which may lead to impaired 
oxygen extraction and diminished exercise capacity.( 11) Furthermore, many patients with 
HFpEF also exhibit pulmonary artery hypertension.  
1.3 RATIONALE FOR USE OF AN sGC STIMULATOR IN HFpEF 
Based on the key role of NO deficiency lead ing to impaired NO-sGC-cGMP signaling in the 
pathophysiology of the disease, the potential valu e of sGC stimulators in the treatment of HFpEF 
is plausible.( 12, 13) Administration of a single dose of the sGC stimulator riociguat to patients 
with pulmonary hypertension secondary to HFpE F did not have an acute effect on pulmonary 
artery pressures (the primary variable) or pulmo nary arterial wedge pressure, but did result in 
improvements in stroke volum e and a reduction in syste mic vascular resistance.( 14) Chronic 
administration of an sGC stimulator may reduce pulmonary arterial pressures, an effect that 
would be beneficial in patients with HFpEF. 
In a Phase 2b trial in HFpEF patients, the investigational sGC stimulator vericiguat improved 
QOL parameters, an effect that was most pro minently demonstrated by [CONTACT_875537]; a beneficial effect on the biomarker N-terminal pro B-type 
natriuretic peptide (NT-proBNP) or in left atri al (LA) dimension by [CONTACT_875538].( 15)  
Studies of other drugs with effects on intracellula r cGMP, such as sildenafil, have been studied 
for the treatment of HFpEF, a nd the results have been mixed.( 16) In contrast, [ADDRESS_1222809] udy, and after 1 week of treatment in the 
other.( 17, 18) The use of the organic nitrate isosorbi de mononitrate in patients with HFpEF has 
demonstrated no benefit.( 19) Organic nitrates release NO nonspe cifically, potentially resulting in 
systemic sGC activation and unt argeted smooth muscle relaxati on. Furthermore, released NO 
can react with superoxide to form highly reac tive and damaging peroxyn itrite ion. In contrast, 
sGC stimulators increase local cGMP signaling in tissues and do not generate peroxynitrite. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222810] recent Investigatorâ€™s Brochure.   
[IP_ADDRESS]  Nonclinical Data in Support of Clinical HFpEF Investigations 
Pharmacologic activation of sGC with NO donors has shown cardiac benefit in animal models 
and in the clinic.( 20) The effects of IW-[ADDRESS_1222811] been explored in models of HFrEF and HFpE F. In the Dahl salt-sensitive (DSS) rat model, 
6 weeks of treatment with IW-1973 resulted in lower levels of the cardiac stress marker 
NT-proBNP, lower cardiac weight, higher ejection fraction (EF), and increased left ventricular 
(LV) end systolic internal dimension compar ed to the vehicle-treated control group. IW-1973 
treatment also led to a dose-dep endent reduction in systemic blood pressure (BP), improvements 
in renal function and histology, and a reduction in expression of  fibrotic markers in the DSS 
model. Exposures achieved with repeated ad ministration of 40 mg/d ay IW-[ADDRESS_1222812]-myocardial infarction (MI) model of HFrEF, 
treatment with IW-1973 (10 mg/kg/day) for 8 weeks resulted in significant de crease in levels of 
NT-proBNP and improvements in echocardiograp hic measures LV end systolic area, LV 
end-systolic volume (LVESV), and LV fractiona l area change compared to the control group. 
Together, these data support investigation of IW-1973 as a potential therapy for HFpEF.  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 30 of 95 2. STUDY OBJECTIVES 
Primary  
â€¢ To assess the safety of oral IW-1973 when administered for approximately 12 weeks to 
patients with HFpEF 
â€¢ To evaluate the effect of oral IW-1973 on p eak exercise capacity when administered for 
approximately 12 weeks to patient s with HFpEF, both in all pa tients and in patients without 
permanent or persistent atrial fibrillation  
 
Secondary   
â€¢ To evaluate the effect of oral IW-1973 on exercise and functional capacity when 
administered for approximately 12 weeks to patients with HFpEF  
 
Exploratory   
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222813] 40% and who have at least 2 of 4 ri sk factors for HFpEF (d iabetes/prediabetes, 
hypertension, obesity, advanced age) (see Eligibility Criteria ). Patients will be stratified by [CONTACT_875539] 2 RUÂ• of age- and sex-adjusted normal 
values with respi[INVESTIGATOR_17864] [RER] Â•DVGHWHUPLQHGE\ FDUGLRSXOPRQDU\H[HUFLVH
test [CPET]) and randomized in a 1:[ADDRESS_1222814] acebo, as described in 
Section 3.5.2 . The number of patients admitted with permanent or persistent atrial fibrillation 
will be limited to under 20% of target enrollment ( Â”36 patients).  
The study will consist of [ADDRESS_1222815] periods , a Screening Period, a Treatment Period, and a 
Follow-up Period ( Figure 1 ). 
Figure 1. Study Schematic 
 
 Follow-up
Vis it
(Day 113 Â±7)Scr eening *
Vis it 
(Day -45 to -3)Randomization
Vis it
(Day 1)End of  Tr eatment
Vis it
(Day 85 -7/+4)Scr eening 
Period Treatment
PeriodFollow-up 
Period
Up to 45 days 85 (-7/+4) days 28 (Â±7)days
Week 2 
Visit
(Day 15 Â±3)Week 4
Visit
(Day 29 Â±3)Week 8
Visit
(Day 57 Â±3)
40 mg IW-1973 daily
BID QD
1 and 2 3 to 12Dosing
WeekPlaceboBaseline*
Vis it
(Day -14 to -3)
*Screening and Baseline 
Visits may be combined if visit occurs within 14 
days of Randomization 
and patient has fasted 
Â•K
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 32 of 95 Screening Period :  The Screening Period will begin with the signature [CONTACT_875567] [ADDRESS_1222816] (6MWT) must occur within the 
14-day period before Randomization. 
Treatment Period: The Treatment Period will begin on Day 1 at Randomization and will end 
after the End of Treatment Visit on Day 85 (-7/+4 da ys). At the Day 1 Visit, eligible patients will 
be stratified as de scribed in Section 3.1 and randomized as de scribed in Section 3.5.2  to receive 
daily IW-1973 or placebo for approximately 12 week s. Dosing on Days 1 to 14 (Â±3) will be BID 
(twice daily); dosing on Day 15 (Â±3) onward will be QD (once daily).  
At the Randomization (Day 1) Visit, patients will receive their morning BID dose of study drug 
in the clinic. At the Week 2 Visit (Day 15 [Â±3]), patients will return to the clinic and receive their 
QD dose of study drug in the clinic. Patients w ill undergo safety, efficacy,  and PK assessments, 
including blood and urine collecti ons at prespecified times (see Schedule of Events ) and will 
receive study drug supply. At both visits, pa tients must stay in the clinic a minimum of 
approximately [ADDRESS_1222817] the clinic at the 
Investigatorâ€™s discretion. 
At the Week 4 Visit, Week 8 Visit, and End of Tr eatment Visit, patients will return to the clinic 
for study drug administration; safety, efficacy , and PK assessments; a nd study drug and other 
supplies, as applicable. 
Follow-up Period:  The Follow-up Period will begin immediately after the End of Treatment 
Visit on Day 85 (-7/+4 days) and will last for 28 (Â±7) days. On Day 113 (Â±7 days), patients will 
return to the clinic for the final Follow-up Visit (see Schedule of Events ). 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 33 of 95 3.2 DISCUSSION OF STUDY DESIGN AND CONTROL GROUP 
A double-blind, placebo-controlled, randomized study design was chosen to provide comparable 
treatment groups and minimal chance of selection or investigator bias in accordance with the 
concepts in ICH E10, Choice of Control Groups  and Related Issues in Clinical Trials 
(International Conference on Ha rmonisation of Technical Requi rements for Registration of 
Pharmaceuticals for Human Use, 2001). Placebo was c hosen as the control to determine the rate 
of spontaneously occurring treatment-emergen t adverse events (TEAEs) and to reduce the 
potential for bias in the reporting of AEs.  
This study has a 12-week Treatment Period to compare the effects of IW-[ADDRESS_1222818] in a relatively small number of patients.( 21) The 6MWT ( Appendix 6 ) provides a simple 
assessment of functional capacity that is easy to perform, requires no equipment or advanced 
training, and is based on an activity of daily liv ing. Because subjects sel ect their own exercise 
intensity, the 6MWT reflects everyday functi onal capacity and provides a global evaluation of 
the organ/physiologic systems involved in exercise.( 22) Assessments will also include patient-
reported questionnaires that  assess health status, generic and disease-specific QOL, symptoms of 
depression, and functional disability. These assessments allow a better understanding of the trial 
population at baseline as well as an evaluati on of the potential impact of IW-1973 treatment on 
patientsâ€™ own assessments of their health and QOL. 
Patients will be stratified by [CONTACT_875540] 2 (CPET) to minimize the potential impact of 
baseline disease severity imbalance between treatment groups. In a ddition, patients will be 
stratified by [CONTACT_875541].   
Enrichment is utilized in this study design by [CONTACT_875542] 20% of target enrollment. This design ensures 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 34 of 95 that a standalone study population of patients without permanent or persistent atrial fibrillation is 
adequately powered to evaluate efficacy.  
Individual stoppi[INVESTIGATOR_875515] (DMC) safety reviews (Section 3.7) 
ensure that individual and/or all dosing will stop should an unacceptable safety signal be 
detected. Patients will have a Follow-up Visit at the clinic 28 (Â±7) days after their final dose of study drug to determine if any AEs have developed and if any AEs that were ongoing at the time 
of discharge have resolved. In addition, at the Foll ow-up Visit as well at each study visit, female 
patients of reproductive potential will have a pregnancy test. 
3.[ADDRESS_1222819] 40% and limited exercise capacity (peak VO
2 <80% of age- and sex-adjusted 
normal values). In additi on, patients must have at least 2 of  the following 4 risk factors for 
HFpEF: diabetes/prediabetes, hypert ension, obesity, and/or advanced age Â•\HDUV .  
The number of patients admitted with permanent or persistent atrial fibrillation will be limited to 
approximately 36, total, in the study. 
For details, see Eligibility Criteria . 
3.4.[ADDRESS_1222820] completed the study after completing the Follow-up Visit on 
Day 113 (Â±7). 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 35 of 95 Patients will be informed that they are free to withdraw from the study at any time and for any 
reason. The Investigator may remove a patient fro m the study if, in the Investigatorâ€™s opi[INVESTIGATOR_1649], it 
is not in the best interest of the patient to continue the study.  Patients may also  be discontinued 
from the study by [CONTACT_875543], including the 
following: 
â€¢ Adverse event(s) 
â€¢ Protocol violation, including lack of compliance 
â€¢ Lost to follow-up (every effort should be made to contact [CONTACT_102]; a certified letter should 
be sent) 
â€¢ Withdrawal of consent (attempts should be ma de to determine the reason for the patient 
withdrawing consent if possible)  
â€¢ Study termination by [CONTACT_1034] 
â€¢ Other reasons (eg, administrative reasons or pregnancy) 
 
The Sponsor will be notified of any premature pa tient discontinuation. The date the patient is 
withdrawn from the study and the reason for discontinuation will be recorded on the study 
termination form of the electronic case report form (eCRF). Patients who discontinue from the 
study will be followed until resolution of all AEs or until the unresolved AEs are judged by [CONTACT_491321]. 
If a patient does not return for a scheduled vis it, the study center should contact [CONTACT_102]. An 
effort will be made to contact [CONTACT_102], including sending a certified letter. In every case, the 
patient outcome, including lost to fo llow-up information, will be documented. 
3.4.2 Early Termination Procedures 
Patients who discontinue study drug for any reason  should complete the assessments required at 
the End of Treatment Visit at the time of their discontinuation and should complete the 
Follow-up Visit 28 Â±7 days after their final dose of study drug. If the End of Treatment Visit 
occurs more than 7 days after the patientâ€™s fina l dose of study drug, the PK blood draw can be 
reduced to 1 sample. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 36 of 95 3.5 STUDY TREATMENT(S) 
3.5.1 Description of Treatment(s) 
[IP_ADDRESS]  Investigational Product 
IW-1973 Tablets are 20-mg oral tablets that  are white, round, and match in appearance. 
[IP_ADDRESS]  Placebo 
Placebo tablets match IW-1973 Tablets in appearance. 
[IP_ADDRESS]  Packaging and Labeling 
IW-1973 and placebo tablets will be  provided by [CONTACT_875544] (Rockford, IL) on behalf 
of Ironwood in 100-cc high-density polyethylene ( HDPE) induction-sealed bottles, 35 tablets per 
bottle, containing two 1-gram mole desiccant sieves and 4 to 6 inches of purified polyester coil.   
[IP_ADDRESS]  Dosage 
For patients randomized through Amendment 2 (or earlier),  Table 3  summarizes the dosage and 
dosing regimen for each treatment arm by [CONTACT_324753]. 
Table 3. Dose Regimen by [CONTACT_875545] 1 and 2, BID Dosing  Weeks 3 through 12, QD Dosing 
10 mg one 5-mg IW-1973 Tablet, orally twice daily two 5-mg IW-1973 Tablets, orally once daily 
20 mg one 10-mg IW-1973 Tablet, orally twice daily two 10-mg IW-1973 Tablets, orally once daily 
40 mg one 20-mg IW-1973 Tablet, orally twice daily two 20-mg IW-1973 Tablets, orally once daily 
Placebo one matching placebo tablet, orally twice dail y two matching placebo tablets, orally once daily 
BID=twice daily; QD=once daily 
 
Beginning with Amendment 3 to the protocol, ne w patients will be randomiz ed to either 40 mg 
IW-1973 or placebo, as summarized in Table 4 . 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 37 of 95 Table 4. Dose Regimen by [CONTACT_875545] 1 and 2, BID Dosing  Weeks 3 through 12, QD Dosing 
40 mg one 20-mg IW-1973 Tablet, orally twice daily two 20-mg IW-1973 Tablets, orally once daily 
Placebo one matching placebo tablet, orally twice dail y two matching placebo tablets, orally once daily 
BID=twice daily; QD=once daily 
 
[IP_ADDRESS]  Storage and Accountability 
IW-[ADDRESS_1222821] be stored under refrigerated conditions, 2Â° to 8Â°C 
(36Â° to 46Â°F) at the study sites. Any deviation from these storage conditions must be reported to 
Ironwood and use of the study drug suspended until re-authorization ha s been provided by 
[CONTACT_357866]. If a temperature excursion above 8Â°C (46Â°F) up to a maximum temperature of 30Â°C 
(86Â°F) occurs for no longer than 24 hours, th e clinical site is authorized by [CONTACT_875546]. If a temperature excursion below 2Â°C (<36Â°F) or above 30Â°C (>86Â°F) occurs for any 
period of time, or from 8 to 30Â°C for a period longer  than [ADDRESS_1222822]. At the end of the study, a co mplete reconciliation of the study drug supplies 
will be performed (ie, tablets will be counted). A copy of the final Drug Accountability Log will 
be provided to Ironwood. All unused and reconc iled drug supplies will be returned to PCI 
Pharma Services or destroyed according to standard institutional policy or per written instruction 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 38 of 95 from Ironwood should an alternate disposition be re quested. No study drug is to be destroyed 
without prior written permission of Ironwood. A co py of the Certificate of Destruction or 
equivalent shall be provided to Ironwood once available.  
3.5.2 Method of Assigning Patien ts to Treatment Groups 
A centralized interactive web response system (I WRS) will be used to randomly assign patients 
to study treatment. The computer-generated randomization schedule will be prepared by [CONTACT_875547] n not otherwise associated with the conduct of the study. 
Approximately 184 patients who meet all of the Inclusion Criteria and none of the Exclusion 
Criteria will be stratified by [CONTACT_875548]/persistent atrial fibrillation status (yes or no) and by 
[CONTACT_875540]
2 (<60% or Â•RIDJH - and sex-adjusted normal values and with 5(5Â•  
as determined by [CONTACT_208203]). An upper limit of a pproximately 36 patients with permanent or 
persistent atrial fibrillation will be set in the IWRS.   
Patients enrolled under Amendment 2 to the protocol (or earlier) were randomized 1:1:1:1 to 
daily 10 mg IW-1973, 20 mg IW-1973, 40 mg IW- 1973, or placebo at the Randomization Visit 
on Day 1. Beginning with Amendment 3 to the pr otocol, new patients w ill be randomized in a 
1:1 ratio to daily doses of either 40 mg IW-1973 or placebo. 
3.5.3 Selection of Dosage in the Study 
This Phase 2 study will evaluate oral IW-1973 (40 mg), administered daily for 12 weeks. The 
dose level selection was or iginally based on data from the following study: 
â€¢ Phase 1b study ICP-1973-102: â€œA 2-stage Phase 1 Study to Evaluate the Safety, Tolerability, 
Pharmacokinetics, and Pharm acodynamics of IW-1973 Tablet  Formulation in Healthy 
Volunteers in an Open-label, Single-dose,  Crossover Stage Followed by a Randomized, 
Double-blind, Placebo-controlled, Multiple-ascendi ng-dose with Optional Up-titration Stageâ€ 
 
In the Phase 1b multiple-ascending-dose (MAD) study (ICP-1973-102), along with preliminary 
data from C1973-201 and C1973-202 that were recei ved subsequent to finalization of the 
original protocol, 40 mg IW-1973 was considered adequately tolerated an d was therefore chosen 
for evaluation in this patient population.  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222823] 2 weeks of dosing is expected to reduce the initial 
time to maximum observed plasma  concentration and to minimize variations in IW-1973 plasma 
concentrations during the approach to steady state, which may improve tolerability.  
3.5.4 Selection and Timing of Dose for Each Patient and Dose Reduction 
[IP_ADDRESS]  Study Drug Administration 
During Weeks 1 and 2, patients will be instructed to take study drug BID (2Ã—/day), as 1 tablet in 
the morning and 1 tablet approximately 12 hours later in the evening, and preferably at 
approximately the same times each day. Starting with the Week 2 Visit (Day 15 Â±3), patients will 
be instructed to take study drug QD (1Ã—/day), as 2 tablets in the morning, preferably at 
approximately the same time each  day. Patients should take stud y drug with water, may take 
study drug with or without food and, for QD dos ing, may swallow the 2 tablets together, if 
desired.  
On study visit days, patients will receive their study drug dose in the clinic. (On Randomization 
Day, patients will receive only their morning dose in  the clinic.) Study vis its should be scheduled 
in the morning to accommodate study drug dos ing schedules and fastin g requirements (Section 
3.6.2 ).  
Permitted concomita nt medications should be taken as usua l, may be taken at the same time as 
study drug, and do not need to be take n in the clinic on study visit days. 
[IP_ADDRESS]  Dose Reduction 
Per Investigator discretion, dose reduction is allowed after consultation with the Medical 
Monitor. If dose reduction is approved, the patient will be allowed to reduce his or her daily dose 
by [CONTACT_2016], ie, from 2 tablets daily to 1 tablet da ily (in the morning). It is recommended for the 
patient to be evaluated in the clinic in association with any dose modification. Each patientâ€™s 
dose may only be reduced once and will not be increased after reduction.  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222824] ug will be dispensed to patients in prelabeled bottles. Patients 
will be asked to return all bottle s (including unused tablets) at the subsequent study visit for 
assessment of compliance with the dosing regimen.  
Treatment compliance will be  based on count of pi[INVESTIGATOR_3353]. 
3.5.[ADDRESS_1222825] and placebo will be supplied as 
oral tablets that match in appearance.  
Unblinding of a patientâ€™s treatme nt assignment is restricted to  emergency situations and should 
only be used under circumstances where knowledge of  the treatment is necessary for safety of 
the patient. Except in a medical emergency, the Investigator and study center staff will remain 
blinded during the conduct of the study and until, at a minimum, all discrepa ncies in the clinical 
database are resolved (ie, at the time of the database lock). Individual patient treatment 
assignment unblinding is available to the Investigator through the IWRS in the event of a 
medical emergency. In advance of breaking the blind, the Investigator should make all 
reasonable efforts to notify and discuss the circ umstances requiring unblinding with the Medical 
Monitor or designee. If the treatment blind is br oken, the reason and the date must be recorded 
and signed by [CONTACT_875549]. If the Investigator  is unblinded to the treatment assignment of a 
patient, the patient will be immediately withdrawn from study drug dosing, and early termination 
procedures (Section  3.4.2 ) should be followed. 
To allow ongoing safety monitoring during the conduct of the study, members of an external 
DMC will review summaries of unblinded safety data. Please refer to Section 5.13 for details. 
3.5.7 Prior and Concomitant Therapy and Procedures 
At the Screening Visit, the following information will be recorded for each patient: 
â€¢ All medications (including name, dosage, a nd schedule) the patient is taking (ongoing) 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 41 of 95 â€¢ All prior medications (including name, dosag e, and schedule) taken during the 30 days 
before the Screening Visit 
â€¢ Prior procedures and surgeries 
 
Beginning at the Screening Visit, any medicatio n (including name, dosage, and schedule) or 
change in medication taken by a patient during the study will be documented in the source 
documents and the eCRF along with the time of use and the reason for use. Also beginning at the 
Screening Visit, any medical procedure or surg ery that the patient unde rgoes will be documented 
in the source documents and the eCRF along with the start and stop date and reason. 
Permitted conco mitant medications should be taken as prescribed, may be  taken at the same time 
as study drug, and do not need to be taken in the clinic on study visit days. 
Prohibited medications and supplem ents are listed in Sections 3.6.1 and Appendix 1 . 
3.6 RESTRICTIONS 
3.6.1 Prohibited Medicines and Supplements 
The following medicines and s upplements are prohibited from 7 days before the Randomization 
Visit (Day 1) through the duration of the trial: 
â€¢ Specific inhibitors of phosphodies terase 5 (PDE5) (including  sildenafil and tadalafil) 
â€¢ Nonspecific inhibitors of PDE5 (including dipyridamole and theophylline) 
â€¢ Any supplements for the trea tment of erectile dysfunction 
â€¢ Riociguat, or any sGC stimulator 
â€¢ Nitrates or NO donors in any form  
 
The following medicines and s upplements are prohibited from 14 days before the Randomization 
Visit (Day 1) through the duration of the trial: 
â€¢ Strong inhibitors of CYP3A; examples in clude azole antifungals, macrolide antibiotics, 
protease inhibitors, diltiazem, and c oncentrated grapefruit supplements 
 
See Appendix [ADDRESS_1222826] of prohi bited medicines and supplements. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222827] overnight (at le ast 8 hours) before all study vis its, except the Screening Visit, 
and will continue fasting until the pre-CPET and predose blood a nd urine samples have been 
collected. See Section 3.8.[ADDRESS_1222828] agree not to make any major changes to their exercise routine from the Screening 
Period through the Follow-up Visit. 
[IP_ADDRESS]  Sexual Activity and Birth Control 
Female patients who are not postmenopausal QRPHQVHVIRUÂ•FRQVHFXWLYHPRQWKV or 
surgically sterile (ie, bilateral oophorectomy, hyst erectomy, or tubal ster ilization [tie, clip, band, 
or burn]), must agree to completely abstain from heterosexual intercourse or, if heterosexually 
active, must agree to use 1 of the following met hods of birth control from the date she signs the 
ICF until 60 days after her final dose of study drug: 
â€¢ Progesterone implant and/or an  intrauterine device (IUD) 
â€¢ Combination of 2 highly effective birth contro l methods (eg, diaphragm with spermicide plus 
a condom, condom with spermicide plus a diaphragm or cervical cap, hormonal 
contraceptive [eg, oral and transdermal patch]  combined with a barrier method, partner with 
YDVHFWRP\>FRQGXFWHGÂ•GD\VEHIRU HWKH6FUHHQLQJ9LVLWRUFRQ ILUPHGYLDVSHUPDQDO\VLV@
plus a hormone or barrier method)   
 
Female patients must wait at least 60 days after the final dose of study drug to try to become 
pregnant and/or to undergo egg donation or eg g harvesting for current or future in vitro 
fertilization. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222829] HULOHE\YDVHFWRP\FRQGXFWHGÂ•  days before the 
Screening Visit or confirmed via sperm analysis), must agree to completely abstain from 
heterosexual intercourse, or, if heterosexually active, must agree to use a highly effective birth 
control method (eg, condom with spermicide, pa rtner IUD, partner diaphragm or cervical cap, 
partner hormonal contraceptive [including proges terone implant], or pos tmenopausal partner [no 
PHQVHVIRUÂ•FRQVHFXWLYHPRQWKV ]) from the Screening Visit through [ADDRESS_1222830] 60 days after 
the final dose of study drug. 
[IP_ADDRESS]  Breastfeeding 
Breastfeeding is not allowed from Screening Visi t through 60 days after the final dose of study 
drug. 
3.7 INDIVIDUAL STOPPI[INVESTIGATOR_875516] 5  are reported during the study and are judged to be both study 
drug related and a serious advers e event (SAE; per causality and SAE definitions in the protocol 
[Section [IP_ADDRESS] ]), individual stoppi[INVESTIGATOR_875517] 3.7.1  and 3.7.2 . The inclusion of these events is based on the clinical experience with 
IW-1973, the prescribing information for the sGC stimulator riociguat ( 23), and the patient 
population for this study.  
Table 5. Categories of SAEs Triggering Individual Stoppi[INVESTIGATOR_875518]-emergent Study Drug-related SAE Category Number of patients to 
trigger DMC review 
Symptomatic hypotension-related events  (eg, syncope) 5 
Spontaneous bleeding events  
(eg, hemoptysis, vaginal hemorrhage, ovarian hemorrhage, subdural 
hemorrhage, hematemesis, hematochezia) 2 
DMC=Data Monitoring Committee; SAE=serious adverse event 
 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 44 of 95 3.7.1 Individual Stoppi[INVESTIGATOR_875519], a patient will be discontinued from study drug dosing if any of the 
following is reported for that patient: 
â€¢ 1 study drug-related spontaneous bleeding SAE 
â€¢ 1 study drug-related symptomatic hypotension-related SAE that is life threatening per 
protocol definition (Section [IP_ADDRESS] ) 
â€¢ 2 study drug-related symptomatic hypotension-related SAEs  
 
At the Investigatorâ€™s or Sponsorâ€™s discretion, an y AE(s) of concern can likewise be the basis for 
patient discontinuation from the trial. 
3.7.2 Data Monitoring Committee Reviews 
An independent DMC will review trial safety data both periodica lly and on an ad hoc basis per 
the SAE criteria in Table 5 (eg, spontaneous bleeding SAEs reported in 2 patients). After each 
periodic or ad hoc review of safety da ta, the DMC will recommend trial continuation, 
continuation with modification, or  termination. Re fer to Section 5.[ADDRESS_1222831] provide written, informed consent. Please see Section 6.2 for more information.  
3.8.2 Medical History 
A complete medical history, including disease- specific history and history of smoking, will be 
recorded at the Screening Visit.  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 45 of 95 3.8.3  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 46 of 95 3.8.4 Physical Examination 
Physical examinations, either complete, symptom- directed, and/or of th e cardiovascular system 
will be performed. A complete physical examinat ion of each patient s hould include assessment 
of the following, at minimum: 
General appearance Head, eyes, ears, nose, and throat 
Cardiovascular system Neck 
Respi[INVESTIGATOR_875520]/liver/spleen Nervous system 
Lymph nodes Skin Neurologic status Mental status 
 
Breast, genitourinary, and rectal examinati ons are optional and may be performed at the 
discretion of the Investigator. For Treatment Period visits, physical exam may be symptom-
directed or limited to cardiovascular system at the Investigatorâ€™s discretion. Any new, clinically 
significant abnormal findings from physical examinations will be reported as an AE. 
Each patientâ€™s weight will be recorded at each study visit; height will only be recorded at the 
Screening Visit. 
3.8.5 Vital Signs  
Vital signs will include seated BP, pulse, respi[INVESTIGATOR_697], and oral temperature (Â°C). All vital 
signs should be measured after the patient has be en sitting quietly for at least [ADDRESS_1222832] 5 minutes before sitting measurements are taken, 
then assume a standing position for 2 minutes (Â± 1 m) before standing measurements are taken.  
3.8.7 NYHA Functional Classification 
At each timepoint, including for purposes of stud y eligibility, each patientâ€™s NYHA classification 
should reflect a contemporane ous assessment of functional status. Note that patients 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 47 of 95 experiencing any functional limitation whatsoever should be classified as NYHA Class II or 
higher. 
Table 6. [LOCATION_001] Heart Association (NYHA) Functional Classification 
Class Description 
I Patients with cardiac disease but without resulting limitation of physical activity. Ordinary 
physical activity does not cause undue fatigue, palpi[INVESTIGATOR_332], dyspnea, or anginal pain. 
II Patients with cardiac disease resulting in slight limitation of physical activity. They are 
comfortable at rest. Ordinary physical activity results in fatigue, palpi[INVESTIGATOR_332], dyspnea, or 
anginal pain. 
III Patients with cardiac disease resulting in marked limitation of physical activity. They are 
comfortable at rest. Less than ordinary activity causes fatigue, palpi[INVESTIGATOR_332], dyspnea, or anginal 
pain. 
IV Patients with cardiac disease resulting in inability to carry on any physical activity without 
discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If 
any physical activity is undertaken, discomfort is increased 
The Criteria Committee of the [LOCATION_001] Heart Association. Nomenclature and Criteria for Diagnosis of Diseases 
of the Heart and Great Vessels. 9th ed. [LOCATION_011], Mass: Little, Brown & Co; 1994:253-56 
 
3.8.8 Blood and Urine Sample Collection 
[IP_ADDRESS]  Clinical Laboratory Tests 
Blood and urine samples will be collected for clin ical laboratory tests. Except for the Screening 
Visit, patients must fast for at least [ADDRESS_1222833] be fasted. Blood samples should be collected after 
electrocardiograms (ECGs) or at least 10 minutes before ECGs, when applicable. 
The clinical laboratory evaluations will include the serum chemistry, hematology (complete 
blood count [CBC]), coagulation, urinalys is, and additional te sts presented in Table 7.  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 48 of 95 Table 7. Clinical Laboratory Tests 
Serum Chemistry Hematology (CBC) Urinalysis 
Albumin Hematocrit Color and appearance 
Alkaline Phosphatase Hemoglobin pH and Specific Gravity 
ALT Platelet count Bilirubin 
AST     MPV Glucose 
Bicarbonate RBC count Ketones 
Bilirubin (total and direct) RBC indices Leukocytes 
BUN     MCH Nitrites 
Calcium     MCHC Occult blood 
Chloride     MCV Protein 
Cholesterol RDW Urobilinogen 
Creatinine WBC count Microscopic :  
GGT WBC differential    Including bacteria, RBCs, WBCs 
Glucose   (% and absolute):    per HPF if dipstick is abnormal 
HDL-c     Basophils  
LDH     Eosinophils Additional blood tests  
LDL-c (calculated)     Lymphocytes Hemoglobin A1c 
Magnesium     Monocytes Fasting plasma glucose 
Phosphorus     Neutrophils Fasting plasma insulin  
Potassium   
Sodium Coagulation  Additional urine tests 
Total Protein aPTT Urine albumin & creatinine for UACR* 
Triglycerides Prothrombin time  
Uric acid INR  
ALT=alanine aminotransferase; aPTT=activated partial thromboplastin time; AST=aspartate aminotransferase; 
BUN=blood urea nitrogen; CBC=complete blood count; GGT=gamma glutamyl transferase; HPF=high power 
field; INR=International Normalized Ratio; LDH=lactat e dehydrogenase; MCH=mean corpuscular hemoglobin; 
MCHC=mean corpuscular hemoglobin concentration; MCV=mean corpuscular volume; MPV=mean platelet 
volume; RBC=red blood cell; RDW=red blood cell distribution width; UACR=urine albumin-creatinine ratio; 
WBC=white blood cell.  
* Samples should be first-void urine samples collected on the morning before or the morning of the applicable 
study visit. Patients will be supplied with specimen  collection supplies at the preceding study visit.  
 
[IP_ADDRESS]  Pregnancy Tests 
For female patients of reproductive potential, a negative pregnancy test (by [CONTACT_72502]) must 
be documented at all study visits  with results available before dosing, when applicable. In the 
event of a positive pregnancy test, the test will be repeated. If pregnancy is confirmed, see 
Section [IP_ADDRESS] . 
Pregnancy tests are not required for female patients who are postmenopa usal (no menses for 
Â• consecutive months) or surgical ly sterile (ie, bilateral oophorec tomy, hysterectomy, or tubal 
sterilization [tie, c lip, band, or burn]). 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 49 of 95 [IP_ADDRESS]  Hepatitis, HIV, and Drug Screens 
Screens for a hepatitis panel and human imm unodeficiency virus (HIV) antibody will be 
performed at the Screening Visit. 
A urine drug screen for the following drugs will be performed at the Screening Visit: 
Amphetamines Cocaine Phencyclidine (PCP) 
Barbiturates Opi[INVESTIGATOR_875521]  
 
 
[IP_ADDRESS]  Urine Creatinine Ratio  
The urine albumin creatinine ratio (UACR) will be calculated as urine albumin (mg/dL) / urine 
creatinine (g/dL).  
Urine albumin and urine creatinine levels will be determined as part of the clinical laboratory 
tests ( Table 7 ). Patients will be given ur ine collection supplies and will collect a first-void urine 
sample on the morning before or the morning of the specified study visit.  
[IP_ADDRESS]  Estimated Glomerular Filtration Rate 
Estimated glomerular filtration rate (eGFR) will be based on the serum creatinine level 
determined as part of the clinical laboratory tests ( Table 7 ) and will be calculated according to 
the Chronic Kidney Disease Epi[INVESTIGATOR_10444] (CKD-EPI) creatinine equation .(29)  
The CKD-EPI [INVESTIGATOR_10908], expressed as a single equation, is  
*)5 Ã®PLQ6FUÈ›Ä® Ã®PD[6FUÈ› -1 209 Ã— 0.993Age Ã— 1.018 [if female] Ã— 1.159 [if black] 
 
ZKHUH6FULVVHUXPFUHDWLQLQHÈ›LVIRUIHPDOHVDQGIRU PDOHVÄ®LV -0.329 for females and -0.411 for males, 
min indicates the minimum RI6FUÈ›  RUDQGPD[LQGLFDWHVWKHPD[LPXPRI6FUÈ›RU  
 
[IP_ADDRESS]  Homeostatic Model Assessment to Es timate Insulin Resistance (HOMA-IR) 
Values from fasting plasma glucose and insulin levels ( Table 7 ) will be used in the Homeostatic 
Model Assessment to estimate insulin resistance (HOMA-IR).( 30, 31 )  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 50 of 95 The HOMA-IR equation is  
HOMA-IR=(FPI Ã— FPG)/22.5, 
where FPI [INVESTIGATOR_875522] (mU/L) and FPG is fasting plasma glucose 
(mmol/L). 
[IP_ADDRESS]    
 
 
 
3.8.[ADDRESS_1222834] 10 minutes after blood 
collections, when applicable. 
3.8.10  Echocardiography 
Echocardiography may be performed at the Screening Visit to confirm eligibility. If performed at 
the Screening Visit, it can be used for base line and does not need to be repeated. If 
echocardiography is not performed at the Screen ing Visit, the baseline echocardiography may be 
performed at either the Baseline or the Randomization Visit (predose). Echocardiography will 
also be performed at the End of Treatment Vis it. When applicable, echocardiography should be 
performed before or at least 1 hour afte r exercise (CPET, 6MWT) is completed. 
Echocardiography measurements for eligibility may be determined by [CONTACT_737]. 
Echocardiography measurements for efficacy analyses will be determined by [CONTACT_10981], 
central Echocardiography Core Lab that is blinded to treatment assignment.  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 51 of 95 At a minimum, the following echocardiographic variables will be determined: 
â€¢ Mitral E/eâ€™ ratio (mitral peak velocity [E]/mitr al annulus early diastolic  recoil velocity [eâ€™]) 
â€¢ LA volume 
â€¢ LVEF 
â€¢ LV chamber dimensions (LVESV and left ventricular end-diastolic volume [LVEDV]) 
â€¢ LV wall thickness (septal and posterior)  
 
3.8.11  CPET 
CPET will be performed using a study-specific protocol; details will be provided in a CPET 
study manual. Each study site will be CPET qualified for the study. Patients must use the same 
form of exercise (treadmill or bicycle) for a ll 3 CPETs, and the method of exercise should be 
recorded in the patient's eCRF. In  general, patients will exercise to peak capacity beginning with 
unloaded exercise and continuing with a symptom-limited incremental ramp to peak VO 2 with 
5(5Â•)RUWKHEDVHOLQH&3(75 (5PXVWEHÂ•)RU:HHNDQG( QGRI7UHDWPHQW&3(7V
SDWLHQWVVKRXOGH[HUFLVHWRPD[ LPXPHIIRUWLGHDOO\WR5(5Â•  
CPET should be performed at the same time of  day (Â±2 h) and should be timed to occur Â•1 hour 
postdose, when applicable. The CPET will preced e the 6MWT when applicable, which will be 
started Â•1 hour after the CPET is completed. 
CPET measurements for eligibility and for efficacy analyses will be determined by [CONTACT_875550]. 
At a minimum, the following measures will be determined: 
x Peak VO 2 (mL O 2/kg/min) 
x RER 
x Ventilatory efficiency (VE/VCO 2 slope) 
x Peak Power Output at Ventilatory Anaerobic Threshold (watts) 
 
Other parameters of interest may be analyzed. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222835] 
The distance, in meters, travelled in 6 minutes will be measured using a study-specific 6MWT 
protocol ( Appendix 6 ). 
The 6MWTs should be performed at approximate ly the same time of day (within a 4-hour 
window) and must be started at least [ADDRESS_1222836] a causal 
relationship with this treatment.  
An AE, therefore, can be any unfavorable and uni ntended sign (including  an abnormal laboratory 
finding, for example), symptom, or  disease temporally associated with the use of a medicinal 
product, whether or not considered related to the medicinal product. 
An AE includes, but is not limited to, the following: 
â€¢ Any unfavorable changes in general condition 
â€¢ Any clinically significant worsening of a preexisting condition 
â€¢ Any intercurrent diseases and accidents 
 
Note:  A procedure is not an AE, but the reason for a procedure may be an AE.  
[IP_ADDRESS]  Causality Assessment 
For all AEs, the Investigator must provide an assessment of causal relationship to study drug. 
The causality assessment must be recorded in th e patientâ€™s source documentation and on the AE 
page of the subjectâ€™s eCRF. Ca usal relationship must be asse ssed according to the following: 
Related:    An event where there is a reasonable possibility of a causal relationship between 
the event and the study drug 
Unrelated:   Any other event 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 53 of 95 [IP_ADDRESS]  Severity Assessment 
The Investigator will provide an assessment of the severity of each AE by [CONTACT_44745] a severity 
rating in the patientâ€™s source documentation a nd on the AE page of the patientâ€™s eCRF. Severity,  
which is a description of the intensity of manifestation of the AE, is distinct from seriousness,  
which implies a patient outcome or  AE-required treatment measure associated with a threat to 
life or functionality. Severity will be assessed according to the following scale: 
Mild : A type of AE that is usually transien t and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual 
activities of daily living. 
Moderate : A type of AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with us ual activities of daily living, causing 
discomfort but poses no significant or pe rmanent risk of harm to the research 
participant. 
Severe : A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.  
 
[IP_ADDRESS]  Serious Adverse Events 
An SAE is defined as any AE occurring at an y dose that results in any of the following 
outcomes: 
â€¢ Death 
â€¢ Life-threatening:  the patient was at immediate risk of death from the reaction as it occurred 
(ie, it does not include a reaction that hypot hetically might have caused death if it had 
occurred in a more severe form) 
â€¢ Hospi[INVESTIGATOR_1081] 
â€¢ Persistent or significant disability/incapacity:  a substantial disruption of a personâ€™s ability to 
conduct normal daily functions 
â€¢ Congenital anomaly/birth defect 
â€¢ Important medical events: events that may not re sult in death, be life threatening, or require 
hospi[INVESTIGATOR_059]. Such an event may be consider ed serious when, based on appropriate medical 
judgment, it may jeopardize the subject and may require medical or surgical intervention to prevent 1 of the outcomes listed in this defin ition. Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency department or at home, 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 54 of 95 blood dyscrasias or convulsions that do not result in inpatient hos pi[INVESTIGATOR_059], or the 
development of drug dependency or drug abuse. 
Emergency room visits that do not result in admi ssion to the hospi[INVESTIGATOR_324735] 1 of 
the other serious outcomes (eg, life-threatening,  other serious [medically important] event). 
[IP_ADDRESS]  Recording Adverse Events 
Adverse events will be collected and recorded from the time the patient signs the ICF at the 
Screening Visit through the Follow-up Visit. All AEs, regardless of the assumption of a causal 
relationship with study procedures or study medica tion, must be recorded in the patientâ€™s source 
documentation and subsequently on the appropriate AE page of th e patientâ€™s eCRF. This record 
includes AEs the patient reports spontaneously, those observed by [CONTACT_737], and those 
elicited by [CONTACT_139667]-ended questions during the study, such as â€œHave 
you had any health problems since your last visit?â€ 
For every AE, the Investigator must: 
â€¢ Provide an assessment of the severity, caus al relationship to the study medication, and 
seriousness of the event 
â€¢ Document all actions taken with regard to  the study medication (ie, no action taken, 
treatment temporarily interrupte d, or treatment discontinued)  
â€¢ Detail any other treatment measures taken for the AE, including concomitant medications 
and/or procedures 
 
Pretreatment AEs will be collected from the time the patient signs the ICF until the patient 
receives study drug. 
Laboratory abnormalities and change s in vital signs, physical examination findings, and 12-lead 
ECG parameters should be considered AEs and repor ted on the AE page of the patientâ€™s eCRF if 
the Investigator considers them clinically significant and/or they necessitate intervention. 
Any medical condition that is present when a patient  is screened and does not worsen in severity 
and/or frequency should be repor ted as Medical History and not as an AE. However, if the 
condition does deteriorate in severi ty and/or frequency at any time during the study, it should be 
reported as an AE. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 55 of 95 [IP_ADDRESS]  Reporting Serious Adverse Events 
All AEs that meet any of the serious criteria must be reported to Medpace Clinical Safety within 
[ADDRESS_1222837]â€™s source documentation and, subsequent ly, entered into the electronic data capture 
(EDC) system on the appropriate AE reporting page  of the subjectâ€™s eCRF, whether or not an 
event is considered causally related to study medication. Once the AE eCRF has been completed 
or updated, Medpace Safety will  be notified electronically and retrieve the form.  
If an event meets serious criteria and it is not pos sible to access the EDC system, the site should 
send an e-mail to Medpace Safety at  or call the 
Medpace SAE Reporting Line (phone number listed below), and fax the completed paper Back 
Up SAE form to Medpace Safety (fax number listed below) within [ADDRESS_1222838] Information for Medpace Clinical Safety: 
Safety Inbox E-mail:  
SAE Reporting Line:  
Safety Fax:  
When follow-up is obtained or requested by [CONTACT_875551], the additional information 
should be recorded on AE eCRF (as applicable) or sent to Medpace Clinical Safety within 
24 hours of receipt by [CONTACT_779]. Copi[INVESTIGATOR_875523], consultant reports, autopsy 
reports, and any other relevant  documents may be requested. 
Appropriate remedial measures s hould be taken by [CONTACT_324762]/her best medical 
judgment to treat the SAE. These measures and the patientâ€™s response to these measures should 
be recorded. All SAEs, regardle ss of relationship to study medi cation, will be followed by [CONTACT_875552], until the Investigator deems the SAE to be chronic or 
stable, or until the patient is lost to follow- up. Clinical, laboratory, and diagnostic measures 
should be employed by [CONTACT_875553]. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 56 of 95 The Investigator will be responsible for reportin g all SAEs to the IRB/IEC, as applicable. 
Ironwood will be responsible for repor ting to the regulatory authorities. 
Special Situation: Exposure to Study Drug During Pregnancy  
A patient who reports pregnancy before study drug randomizati on must be withdrawn from the 
study. The pregnancy will be recorded as a reason for screen failure. Since there will have been no exposure to study drug, there will be no need to notify Medpace Clinical Safety of the 
pregnancy. 
A patient who reports pregnancy after randomization must discontinue study drug at once. The 
site must notify Medpace Clinical  Safety within [ADDRESS_1222839] 
learn of the pregnancy (via email or SAE Reporting line). Medpace Clinical Safety will send the 
site an Exposure in Utero (EIU) Form for co mpletion within 24 hours. The site should make 
reasonable efforts to follow the pregnancy to te rm and notify Medpace Clinical Safety of the 
pregnancy outcome (within 24 hours of being informed ) or if outcome is associated with an SAE 
(eg, if the mother is hospi[INVESTIGATOR_057], spontaneous  abortion, congen ital anomaly), the site should 
follow SAE reporting procedur es, as discussed above. 
3.8.14  Cardiac Events  
Hospi[INVESTIGATOR_875524], 
independent, blinded cardiac events adjudicator(s).  
3.8.15  Pharmacokinetic Assessments 
Blood samples will be collected for PK assessments. 
3.8.16   
 
 
 
  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 57 of 95 4. STUDY ENDPOINTS 
4.1 PRIMARY ENDPOINTS 
4.1.1 Primary Safety 
â€¢ Incidence of TEAEs and study drug-related TEAEs 
4.1.2 Primary Efficacy 
â€¢ Change from baseline in peak VO 2 (CPET) at Week 12 
 
4.2 SECONDARY ENDPOINTS 
4.2.1 Secondary Efficacy 
â€¢ Change from baseline in 6MWT distance at Week 12 
â€¢ Change in ventilatory efficiency as defined by [CONTACT_128466]/VCO 2 slope (CPET) at Week 12 
â€¢ CPET Responders (Responders are subjects who improve by [CONTACT_2669] 1.5 mL O 2/kg/min in 
peak VO 2 from baseline to Week 12. Subjects who ar e hospi[INVESTIGATOR_875525].) 
4.3 EXPLORATORY ENDPOINTS 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 58 of 95 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
Confidential Page 59 of 95 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 60 of 95 5. STATISTICAL METHODS 
5.1 GENERAL CONSIDERATIONS 
Descriptive statistics (n, mean or geometri c mean, standard devi ation, minimum, median, 
maximum, 25th and 75th percentiles) will be calcu lated to summarize con tinuous variables. Count 
and percentage of patients in each category will be  calculated to summarize categorical variables.  
Additionally, inferential statistical analysis will be performed  on primary and secondary efficacy 
endpoints described in Sections 5.1.1  and 5.1.2 .  
5.1.1 Continuous Endpoints 
For continuous endpoints (eg, absolute change fr om baseline and percen t change from baseline), 
an analysis of covariance (ANCOVA) mode l will be fitted with  treatment group and 
stratification factors as categorical variable te rms and the corresponding baseline efficacy value 
as a covariate. Least squares means (LSMs) and 95% confidence intervals for each treatment 
group as well as LSM difference between the 40-mg IW-1973 group and the placebo group will 
be presented, along with the corresponding conf idence intervals and p-values. The cumulative 
distribution function (CDF) of change from baselin e will be plotted by [CONTACT_1570]. To aid in 
the interpretation of the graphical representation of the CDF across treatments, a two-sample 
Kolmogorov-Smirnov test  will be conducted.  
5.1.2 Responder Endpoints 
For responder endpoints, the proportions of re sponders between the 40-mg IW-1973 group and 
the placebo group will be compared using a Coch ran-Mantel-Haenszel (C MH) test controlling 
for stratification factors. The difference in the proportion of responders between the 40-mg 
IW-1973 group and the placebo group as well as the CMH estimates of odds ratio and p-values 
will be presented, along with the corresponding confidence intervals.  
Additional details regarding the statistical methods will be provided in the Statistical Analysis 
Plan (SAP), to be finalized be fore unblinding of the study. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222840] a si ngle statistical hypothesi s; however, approximately 
184 subjects will provide approx imately 90% power to detect a mean difference of 
1.3 (mL O 2/kg/min) between the 40-mg IW-1973 treatment  arm and the placebo treatment arm in 
change from baseline at Week 12 peak VO 2. This estimate is based on the Evaluable Population 
(defined in Section 5.3), including patients with permanent or persistent atrial fibrillation at 
Screening, and using the follow assumptions:  
â€¢ 5% Type I error for a 2-sided test  
â€¢ Mean Peak VO 2 change from baseline at Week 12 for Placebo arm is 0.0 (mL O 2/kg/min) 
â€¢ Mean Peak VO 2 change from baseline at Week 12 for 40 mg IW-1973 is 1.3 (mL O 2/kg/min) 
â€¢ Equal standard deviation for a ll treatment arms at 2.5 (mL O 2/kg/min) for change from 
baseline at Week 12 
â€¢ 10% attrition prior to Week 12 CPET 
â€¢ 10% of the total number of pa tients were randomized to eith er the 10- or 20-mg IW-1973 
dose groups under Amendment 2 of the protocol (or earlier)  
â€¢ Reduced treatment effect for IW-1973 in subjec ts with permanent or persistent atrial 
fibrillation at Screening 
 
Additionally, under similar assumpti ons, this sample size will also  provide 90% power to detect 
a mean difference of 1.5 (mL O 2/kg/min) on the same endpoint on the well-defined subgroup of 
a minimum of approximately 148 patie nts without permanent or pers istent atrial fibrillation at 
Screening.   
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222841] 1 evaluable baseline measurement.  
Evaluable Population All patients in the mITT who complete 8 weeks of dosing (Â±3 days) 
and have at least [ADDRESS_1222842] 1 dose of IW-1973 
ITT=intent to treat; mITT=modified intent to treat 
 
5.4 PATIENT DISPOSITION 
The total number of screened patients and the number of patients who are screen failures will be 
tabulated. The number of patients who were ra ndomized and the number and percentage of 
patients included in each popula tion will be presented by [CONTACT_64240]. The number and 
percentage of patients who completed the study or  discontinued early, as well as the reasons for 
discontinuation, will be presen ted by [CONTACT_1570]. 
5.5 DEMOGRAPHICS AND BASELINE CHARACTERISTICS 
Demographic parameters (eg, age, sex, race, ethnicity, weight, height, BMI and other baseline 
characteristics will be summarize d by [CONTACT_875554], Evaluable, and modified 
intent-to-treat (mITT) Populations, using de scriptive statistics as  defined in Section 5.1.  
5.[ADDRESS_1222843]. Compliance will be based on the number of doses expected to 
be taken. Percent compliance for study medication will be summarized by [CONTACT_875555] e ITT Population. Complianc e rates will also be 
FDWHJRUL]HGDVPLVVLQJ Â•DQGÂ”DQG! , and summarized by [CONTACT_6490].  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222844] dose of study drug will not be considered concomitant for purposes of analysis. Both prior and concomitant medicine use will be summarized by [CONTACT_875556]-to-treat (ITT) Population. Multiple medici nes within the same 
category (based on Anatomical-T herapeutic-Chemical classifica tion) will only be counted once 
for that patient. 
5.8 MAJOR PROTOCOL DEVIATIONS 
Major protocol deviations will be identified and documented based on a review of protocol 
deviations before database lo ck and treatment unblinding. The categories of major protocol 
deviations to be reviewed include, but are not limited to , patients who: 
â€¢ Did not meet key inclus ion/exclusion criteria 
â€¢ Received disallowed concomitant medication(s) that could meaningfully impact 
interpretation of study results 
â€¢ Had overall treatment compli ance rate <80% or >120% 
 
The number and percentage of subjects with major protocol deviations will be summarized by 
[CONTACT_875557]. All major protocol deviations 
will be presented in a data listing. 
5.9 EFFICACY ANALYSES 
5.9.1 Controlling for Multiplicity 
Due to the exploratory nature of this study, there is no adjustment on the p-values for multiple 
testing. All reported p-values are considered nominal. A p- YDOXHÂ”LQGLFDWHVWKDWWKH
treatment samples are less likely to have been drawn from the same distribution by [CONTACT_29745]. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 64 of 95 5.9.2 Analyses on the Primary Efficacy Endpoint 
An ANCOVA analysis as described in Section 5.1.1  will be performed on the primary efficacy 
endpoint as defined in Section 4.1.2  with treatment group and stratif ication factors as categorical 
variable terms and the corresponding baseline CPET value as a covariate on each of the 
following 2 populations: 
â€¢ Evaluable Population   
â€¢ A subgroup of the Evaluable P opulation, excluding patients who ha d permanent or persistent 
atrial fibrillation at baseline 
Sensitivity analyses similar to the above analys is will be performed on each of the above 
[ADDRESS_1222845]. Patients with no 
postbaseline CPET measurement will be assigned 0 as improvement, or no change from baseline. 
Details of the sensitivity analysis will be included in the SAP.  
5.9.3 Analyses on the Secondary Efficacy Endpoints 
All secondary and exploratory analyses will be  performed on the Evaluable Population and a 
subgroup of the Evaluable Popula tion excluding patients with perm anent or persistent atrial 
fibrillation at baseline.  
ANCOVA models described in Section 5.1.1  will be used to compare the 40-mg IW-1973 group 
with the placebo group on the following secondary endpoints. 
â€¢ Change from baseline in 6MWT distance at Week 12   
â€¢ Change in ventilatory efficiency as defined by [CONTACT_128466]/VCO 2 slope (CPET) at Week 12   
 
Proportions of responders based on CPET will be compared using a responder analysis as 
described in Section 5.1.2 . 
Details of other analysis, such as exploratory analysis 
 
   
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222846] version of Medical Dictionary for Regulatory 
Activities (MedDRA) available at the start of the study and will be summarized by [CONTACT_53157] (SOC), pref erred term (PT), and treatment group. Listings will be provided 
for pretreatment AEs, TEAEs, severe AEs, st udy drug-related AEs, SAEs, and AEs leading to 
study discontinuation. 
TEAEs are those AEs that started or worsened in severity after the administration of study drug. 
TEAEs will be summarized for each treatment group by [CONTACT_3592]; PT and severity, by [CONTACT_2946]; 
PT and relationship to study drug ; and by [CONTACT_2946], PT. If a patient has more than [ADDRESS_1222847] relationship to study drug.  
In addition, the incidence of AEs leading to pr emature discontinuation of study drug will be 
summarized by [CONTACT_1570]. Listings of pret reatment AEs, TEAEs, severe TEAEs, study 
drug-related AEs, SAEs, AEs leading to study di scontinuation, and AEs leading to death (if any) 
will be provided. 
5.10.2  Clinical Laboratory Parameters 
Descriptive statistics for clinical laboratory values (in standard units) and changes from the 
baseline values at each assessment time point w ill be presented by [CONTACT_875558]. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 66 of 95 5.10.3  Vital Signs 
Descriptive statistics for vital signs (ie, pulse rate, systolic and diastolic BP, respi[INVESTIGATOR_697], 
temperature, and body weight) and changes from baseline values at each visit will be presented 
by [CONTACT_1570]. 
5.10.4  ECGs 
Descriptive statistics for ECG parameters and changes from the baseline values at each 
assessment time point will be presented by [CONTACT_1570]. 
The number and percentage of patients with EC G abnormalities that are considered TEAEs by 
[CONTACT_875559]. A listing of all AEs for patients with 
ECG-related TEAEs will also be provided. 
5.11 PK  
PK analyses will be based on the PK Population. Descriptive statistics w ill be calculated for 
plasma concentrations of IW-1973 at each  assessed timepoint by [CONTACT_15449]. 
 
 
 
 
5.12  
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
Confidential Page 67 of 95 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222848] completed 2 w eeks of the Treatment Period (but at least twice every 
12 months, unless a different frequency is deem ed appropriate by [CONTACT_875560]). For these 
periodic reviews, the DMC will be provided with unblinded summaries of TEAE data by 
[CONTACT_6660]. An independe nt statistician will be responsible for summarizing and 
submitting these safety data to members of the DMC. All data presentations for the DMC will be 
performed using the Safety Population. All data th at are available at the time of each analysis 
will be presented. If a safety/tolerability signal or concerning AE imbalance is identified at a 
review, the committee may request additional safety data (eg, vital signs, concomitant 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 69 of 95 medications) At each meeting, the DMC will review cumulative TEAE data and recommend trial 
continuation, modifica tion, or termination. 
The DMC will also be required to perform ad hoc review(s) per SAE criteria in Table [ADDRESS_1222849], the subjectsâ€™ 
unblinded treatment and dose level information will be provided to the committee.  
In addition to the periodic and ad hoc reviews, during the trial, committee members will be 
provided with blinded reports on all SAEs.  
The DMC or the Sponsor may request ad hoc m eetings at any time and at their discretion. 
There are no predefined stoppi[INVESTIGATOR_875526] e trial (for individual stoppi[INVESTIGATOR_004], see 
Section 3.7.1 ). However, the Sponsor, upon the recommendation of the DMC, may stop the 
study at any time for significant safety concer ns. If the DMC recommends stoppi[INVESTIGATOR_875527], a senior review team from the S ponsor will have the opportunity to review the 
blinded/unblinded data and discuss study finding s with the DMC. The Sponsor may also seek 
input from relevant regulatory authorities. Th e Sponsor will make the final decision on the 
recommendation and will relay its decision to the DMC and relevant regulatory authorities. 
Additional details will be provided in the DMC charter, which will be developed in collaboration 
with the DMC members and will be finalized before the first patient is randomized. 
5.14 INTERIM ANALYSES 
Planned interim safety analyses will be performed for the sole purpose of providing preliminary 
safety analyses to the DMC (Section 5.12.4 ).  
An additional optional interim analysis to review  unblinded efficacy data to assist with the 
planning of future studies may be  performed after at least one ha lf of the anticipated subjects 
(NÂ•92) have completed the last visit. If performed, details regarding the interim analysis will be 
included in the SAP, along with updates to th e data management plan as necessary. An 
independent statistic ian (who will not be involved in study data collection or  interpretation) 
performing the interim analysis and Ironwood staff members, as identified in the SAP, may be 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222850] OF THE STUDY OR PLANNED 
ANALYSES 
Any amendment to this protocol will be provided to the Investig ator in writing by [CONTACT_645755]. Before implementation, any protoc ol amendment regarding reportable deviations 
(as defined by [CONTACT_1201]/IEC) must  be approved by [CONTACT_1201]/IEC a nd the signature [CONTACT_324790] [CONTACT_645756], with the following 
exception: If the protocol is amended to eliminate or reduce the risk to patients, the amendment 
may be implemented before IRB/IEC review a nd approval. However, the IRB/IEC must be 
informed in writing of such an amendment, and approval must be obtained within reasonable 
time limits. 
Deviating from the protocol will be  permitted only if absolutely necessary for the safety of the 
patients and must immediately be repo rted to Ironwood or its designee. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222851]/INSTITUTIONAL ETHICS 
COMMITTEE 
Before the study onset, the protocol, any protocol  amendments, ICFs, advertisements to be used 
for patient recruitment, and any other written information regarding this study to be provided to a 
patient or patientâ€™s legal guardian must be approved by [CONTACT_875561] 
(IRB) or Institutional Ethics Committee (IEC). 
All IRB/IEC approvals must be dated and signed by [CONTACT_1201]/IEC Chairperson or his or her 
designee and must identify the IRB/IEC by [CONTACT_45972], the clinical protocol by [CONTACT_29985]/or 
protocol number, and the date  upon which approval or favorable opi[INVESTIGATOR_324740]. Copi[INVESTIGATOR_1099]/IEC ap provals will be forwarded to Ironwood. All 
correspondence with the IRB/IEC should be maintained in the Investigator File. 
No drug will be released to the site to dose a patient until written IRB/IEC approval has been 
received by [CONTACT_357866]. 
The Investigator is responsible for obtaining conti nuing review of the clinical research at least 
annually or more often if specified by [CONTACT_1201]/ IEC. The Investigator must supply Ironwood with 
written documentation of the approval of the continued clinical research. 
The IRB/IEC must be constituted in accord ance with ICH Good Clinical Practice (GCP) 
guidelines and any relevant and app licable local and national regulations. 
Major changes in this research activity, except those to remove an apparent immediate hazard to 
the patient, must be reviewed and approved by [CONTACT_645757]/IEC that approved the 
study. Amendments to the protocol must be submitted in writing to the Investigatorâ€™s IRB/IEC 
for approval before patients being enrolled into the amended protocol. 
6.2 PATIENT INFORMATION AND INFORMED CONSENT 
Informed consent procedures will comply with  the Code of Federal Regulations (CFR) 21, 
Parts 50 and 312. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222852] be approved by [CONTACT_1201]/IEC for the purposes of obtaining and 
documenting consent. 
Before entry into the study, each patient will be provided with a written explanation of the study. 
It is the responsibility of the Investigator or appr opriately trained health professional to give each 
patient full and adequate information regarding the objectives and procedures of the study and 
the possible risks involved. Patients will then be given the opportunity to ask questions and the 
Investigator will be available to answer questions as needed. Patients will be informed of their 
right to withdraw from the study at any time wit hout prejudice. After this explanation and before 
entering the study, the patient will voluntarily sign the study-specific ICF. The patient will 
receive a copy of the signed and dated ICF. The Investigator must retain each patientâ€™s original 
signed ICF. 
If new information becomes available that ma y be relevant to the patientâ€™s consent and 
willingness to participate in the study, the ICF will be revised and the patient will be 
reconsented. The revised ICF must be submitted to the IRB/IEC for review and approval before 
its use. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 73 of 95 7. INVESTIGATORS AND STUDY ADMINISTRATIVE 
STRUCTURE 
This study will be performed at multiple study sites. The Investigator at each study site will be 
responsible for ensuring that the study is c onducted according to the signed Clinical Trial 
Agreement, the protocol, IRB/IEC requirements, and ICH GCP guidelines. 
The Investigator will be responsible for the overs ight of the siteâ€™s conduct of the study, which 
will consist of completing all protocol assessments, maintaining the study file and the patient 
records, drug accountability, corresponding with the IRB/IEC, and completing the eCRF. 
7.[ADDRESS_1222853] be consistent wi th the patientâ€™s source 
documentation. 
During the course of the study, the Clinical Site Monitor will make study site visits to review 
protocol compliance, compare eCRFs and indivi dual patientâ€™s medical re cords, assess drug 
accountability (in a blinded manner), and ensure that  the study is being conducted according to 
pertinent regulatory requirement s. All eCRFs will be verified with source documentation. The 
review of medical records will be performed in a manner that ensures patient confidentiality is 
maintained. 
The Clinical Site Monitor will discuss instances of missing or uninterpretable data with the 
Investigator for resolution. Any changes to th e study data will be ma de to the eCRF and 
documented via an electronic audit trail associated with the affected eCRF. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222854] agree to allow Ironwood, representatives of 
Ironwood, or the Food and Drug Administration (FDA) or other regulatory agencies access to all 
study records. 
7.3 ELECTRONIC CASE REPORT FORMS AND DATA MANAGEMENT 
Study data will be recorded in the patientâ€™s source documentation and entered in eCRF in 
Ironwood or designee's EDC system. Source do cumentation supporting th e eCRF data should 
indicate the patientâ€™s participation in the stud y and should document the dates and details of 
study procedures, AEs, all observa tions, and patient status. The Investigator is responsible for 
verifying that all data entries on the eCRFs are accu rate and correct and ensuring that all data are 
entered in a timely manner, as soon as possible af ter the information is collected. An explanation 
should be provided for any missing data. The Inve stigator must provide through the EDC system 
his or her formal approval of all the informa tion in the eCRFs and changes to the eCRFs to 
endorse the final submitte d data for each patient. 
Ironwood will retain the final eCRF  data and corresponding audit trails. A copy of the final 
archival eCRF in the form of a compact disc or other electronic media will be placed in the 
Investigatorâ€™s study file. 
A record of screen failures and pretreatment failures will be maintained for patients who do not 
qualify for enrollment, including the reason for the failure. 
7.[ADDRESS_1222855] of 
the study by [CONTACT_875562] 
(telephone, e-mail, letter, a nd fax) with the study sites. The site monitor will ensure that the study 
is conducted according to the protocol and regulato ry requirements. During monitoring visits, the 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222856] of 
the monitor, auditor, IRB/IEC, or regulatory authority, the Investigator should make all requested 
study-related records available for direct access. 
All aspects of the study will be carefully mon itored by [CONTACT_875563]. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222857]: 
â€¢ Return all study medications and any study ma terials to Ironwood; alternatively, study 
medication may be destroyed on site  with prior approval by [CONTACT_357866]  
â€¢ In cases where the Investigator opts to self-terminate, provide a written statement describing 
why the study was terminated prematurely 
 
Ironwood may terminate the study in its entirety or at a specific center at any time for any 
reason, including but not limited to the following: 
â€¢ Failure to enroll patients 
â€¢ Protocol violations 
â€¢ Inaccurate or incomplete data 
â€¢ Unsafe or unethical practice 
â€¢ Questionable safety of the study medication 
â€¢ Suspected lack of efficacy of the study medication  
â€¢ Administrative decision 
 
8.[ADDRESS_1222858] to agreement between the 
Investigator and Ironwood. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222859] each patientâ€™s use. A complete 
reconciliation of study medication will be performed at the site close-out visit with a final 
accountability log provided to Ironwood as part of the site close-out repo rt. Written approval for 
return of all unused and reconc iled study medication or destruc tion by [CONTACT_875564]. No study medication may be destroyed by 
[CONTACT_875565]. 
9.[ADDRESS_1222860] results, and medication inventory 
records, for a period of 2 years following the da te a marketing applica tion is approved for the 
drug for the indication for which it is being investig ated; or, if no application is to be filed or if 
the application is not approved for such indication, until [ADDRESS_1222861] retention of records fo r a longer period of time; therefore, no study 
records shall be destroyed without notifying Spon sor and giving Sponsor the opportunity to take 
such study records or authorizing in writing the de struction of records after the required retention 
period. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222862] be transferre d to another person (Ironwood, IRB, or other 
Investigator) who will accept this responsibility. Ironwood must be notified of and agree to the 
change in advance. 
9.[ADDRESS_1222863] on which the patient ID number and the full name, address, and 
telephone number of each  patient is listed. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-[ADDRESS_1222864] 
1. Fletcher GF, Balady G, Froelicher VF, Ha rtley LH, Haskell WL, Pollock ML. Exercise 
standards. A statement for healthcare profe ssionals from the American Heart Association. 
Writing Group. Circulation. 1995;91(2):580-615. 
2. Dhingra A, Garg A, Kaur S, Chopra S, Batra JS, Pandey A, et al. Epi[INVESTIGATOR_875528]. Curr Heart Fail Rep. 2014;11(4):354-65. 
3. Oktay AA, Rich JD, Shah SJ. The emerging epid emic of heart failure with preserved ejection 
fraction. Curr Heart Fa il Rep. 2013;10(4):401-10. 
4. Bhuiyan T, Maurer MS. Heart Failure with Pres erved Ejection Fraction: Persistent Diagnosis, 
Therapeutic Enigma. Curr Cardi ovasc Risk Rep. 2011;5(5):440-9. 
5. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC, Committee ASA, et al. 
Clinical presentation, manageme nt, and in-hospi[INVESTIGATOR_875529]: a report from the Acute 
Decompensated Heart Failure National Regist ry (ADHERE) Database. J Am Coll Cardiol. 
2006;47(1):76-84. 
6. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epi[INVESTIGATOR_875530]. Eur J Heart Fail. 2011;13(1):18-28. 
7. Shah SJ, Heitner JF, Sweitzer NK, Ana nd IS, Kim HY, Harty B, et al. Baseline 
characteristics of patients in the treatment of preserved cardiac function heart failure with an 
aldosterone antagonist trial. Circ Heart Fail. 2013;6(2):184-92. 
8. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, et al. Phenotype-
Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation. 2016;134(1):73-90. 
9. Paulus WJ, Tschope C. A novel paradigm for he art failure with preser ved ejection fraction: 
comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammati on. J Am Coll Cardiol. 2013;62(4):263-71. 
10. Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ, Bradshaw AD, et al. Myocardial 
stiffness in patients with heart failure and a preserved ejection fracti on: contributions of 
collagen and titin. Circ ulation. 2015;131(14):1247-59. 
11. Dhakal BP, Malhotra R, Murphy RM, Pappagianopoulos PP, Baggish AL, Weiner RB, et al. 
Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extrac tion. Circ Heart Fail. 2015;8(2):286-94. 
12. Dubin RF, Shah SJ. Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for 
Heart Failure Associated with Cardiorena l Syndromes? Curr Heart Fail Rep. 2016;13(3):132-
9. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 80 of 95 13. Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Bohm M, et al. Soluble 
guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev. 2013;18(2):123-34. 
14. Bonderman D, Pretsch I, Steringer-Mascherbauer R, Jansa P, Rosenkranz S, Tufaro C, et al. 
Acute hemodynamic effects of ri ociguat in patients with pulmo nary hypertension associated 
with diastolic heart failure (DILATE-1) : a randomized, double-blind, placebo-controlled, 
single-dose study. Chest. 2014;146(5):1274-85. 
15. Pi[INVESTIGATOR_88082] B, Maggioni AP, Lam CSP, Pi[INVESTIGATOR_88082]-K raigher E, Filippatos G, Butler J, et al. 
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: 
results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) st udy. Eur Heart J. 2017;38(15):1119-27. 
16. Zhuang XD, Long M, Li F, Hu X, Liao XX, Du ZM. PDE5 inhibitor sildenafil in the 
treatment of heart failure: a meta-analysis of randomized controlled trials. Int J Cardiol. 2014;172(3):581-7. 
17. Eggebeen J, Kim-Shapi[INVESTIGATOR_405364], Haykowsky M, Morgan TM, Basu S, Brubaker P, et al. One 
Week of Daily Dosing With Beetroot Ju ice Improves Submaximal Endurance and Blood 
Pressure in Older Patients With Heart Failure  and Preserved Ejection Fraction. JACC Heart 
Fail. 2016;4(6):428-37. 
18. Zamani P, Rawat D, Shiva-Kumar P, Geraci S, Bhuva R, Konda P, et al. Effect of inorganic 
nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation. 
2015;131(4):371-80; discussion 80. 
19. Redfield MM, Anstrom KJ, Levine JA, Koepp GA , Borlaug BA, Chen HH, et al. Isosorbide 
Mononitrate in Heart Failure with Pres erved Ejection Fraction. N Engl J Med. 
2015;373(24):2314-24. 
20. Bian K, Doursout MF, Murad F. Vascular syst em: role of nitric oxide in cardiovascular 
diseases. J Clin Hypertens (Greenwich). 2008;10(4):304-10. 
21. Balady GJ, Arena R, Sietsema K, Myers J, Coke  L, Fletcher GF, et al. Clinician's Guide to 
cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circula tion. 2010;122(2):191-225. 
22. Laboratories ACoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J 
Respir Crit Care Me d. 2002;166(1):111-7. 
23. ADEMPAS Prescribing Information.: Ba yer Healthcare Inc.; 2013. Available from: 
http://labeling.bayerhealthcare.co m/html/products/pi/Adempas_PI.pdf. 
24. Green CP, Porter CB, Bresnahan DR, Spertus JA . Development and evaluation of the Kansas 
City Cardiomyopathy Questionnaire: a new health  status measure for heart failure. J Am Coll 
Cardiol. 2000;35(5):1245-55. 
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
 
Confidential Page 81 of 95 25. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P,  Janavs J, Weiller E, et al. The Mini-
International Neuropsychiatric Interview (M.I .N.I.): the development and validation of a 
structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 
1998;[ADDRESS_1222865] 20:22-33;quiz 4-57. 
26. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. 
The EuroQol Group. Health Policy. 1990;16:199-208. 
27. Bairey Merz CN, Handberg EM, Shufelt CL, Mehta PK, Minissian MB, Wei J, et al. A 
randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary 
microvascular dysfunction (CMD): impact on an gina and myocardial perfusion reserve. 
European heart journal. 2016;37(19):1504-13. 
28. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item 
Quick Inventory of Depressive Symptomatology  (QIDS), clinician rating (QIDS-C), and self-
report (QIDS-SR): a psychometri c evaluation in patients with chronic major depression. Biol 
Psychiatry. 2003;54(5):573-83. 
29. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new 
equation to estimate glomerular filtration rate. Annals of Internal Medicine. 2009;150(9):604-12. 
30. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes care. 
2004;27:1487-95. 
31. Matthews DR, Hosker JP, Rudenski AS, Naylor  BA, Treacher DF, Turner RC. Homeostasis 
model assessment: insulin resistance and beta- cell function from fasting plasma glucose and 
insulin concentrations in ma n. Diabetologia. 1985;28(7):412-9. 
32. Spertus J, Peterson E, Conard MW, Heiden reich PA, Krumholz HM, Jones P, et al. 
Monitoring clinical changes in patients with  heart failure: a comparison of methods. Am 
Heart J. 2005;150(4):707-15. 
33. Guazzi M, Dickstein K, Vicenzi M, Arena R.  Six-minute walk test and cardiopulmonary 
exercise testing in patients with chronic heart failure: a comparative analysis on clinical and prognostic insights. Circ Heart Fail. 2009;2(6):549-55. 
 

&RQILGHQWLDO 3DJHRI$33(1',; 352+,%,7('0(',&,1( 6$1'6833/(0(176
3URKLELWHGIURPGD\VEHIRUH5DQGRPL]DWLRQWKURXJKWKHGXUDWLR QRIWKHVWXG\
Â‡6SHFLILFLQKLELWRUVRI3'(LQF OXGLQJVLOGHQDILOWDGDODILOYD UGHQDILO
Â‡$OOVXSSOHPHQWVIRUWKHWUHDW PHQWRIHUHFWLOHG\VIXQFWLRQ
Â‡1RQVSHFLILFLQKLELWRUVRI3'( LQFOXGLQJGLS\ULGDPROHWKHRSK\O OLQH
Â‡2WKHUV*&VWLPXODWRU VLQFOXGLQJULRFLJXDW
Â‡1LWUDWHVLQFOXGLQJQLWURJO\FHUL QLVRVRUELGHPRQRQLWUDWHLVRVR UELGHGLQLWUDWHVRGLXP
QLWURSUXVVLGHDP\OQLWUDWH
Â‡2WKHU12GRQRUVLQDQ\IRUPLQFOXGLQJEHHWURRW

3URKLELWHGIURPGD\VEHIRUH5DQGRPL]DWLRQWKURXJKWKHGXUDWL RQRIWKHVWXG\
Â‡6WURQJLQKLELWRUVRI&<3$LQFO XGLQJD]ROHDQWLIXQJDOVHJLW UDFRQD]ROHSRVDFRQD]ROH
FRQLYDSWDQGLOWLD]HPLGHODOLVLEPDFUROLGHDQWLELRWLFVHJF ODULWKURP\FLQWHOLWKURP\FLQ
QHID]RGRQHSURWHDVHLQKLELWRUV HJULWRQDYLUERFHSULYLUDQ GH[FHVVLYHJUDSHIUXLWLQWDNH
RUFRQFHQWUDWHGJUDS HIUXLWVXSSOHPHQWV
&<3 F\WRFKURPH3$12 QLWULFR[LGH3'( SKRVSKRGLHVWHUDVH
IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
&RQILGHQWLDO 3DJHRIIW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
&RQILGHQWLDO 3DJHRIIW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
&RQILGHQWLDO 3DJHRIIW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 

&RQILGHQWLDO 3DJHRI$33(1',; IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 

&RQILGHQWLDO 3DJHRIIW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 

&RQILGHQWLDO 3DJHRIIW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 

&RQILGHQWLDO 3DJHRIIW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 

&RQILGHQWLDO 3DJHRI$33(1',; 0,187(:$/.7(670(7+2'
7KHPLQXWHZDONWHVWZLOOEH FRQGXFWHGDFFRUGLQJWRWKHVWXG\ 0LQXWH:DON0DQXDOZKLFK
LVDGDSWHGIURPWKHJXLGHOLQHVRI WKH$PHULFDQ7KRUDFLF6RFLHW\ ,WLVUHFRPPHQGHGWKDWWKH
VDPHVWXG\FRRUGLQDWRUFRQGXFWH DFKWHVWIRUHDFKDSSOLFDEOHSD WLHQW7KHIROORZLQJ
UHFRPPHQGDWLRQVVKRXOGEHIROORZHG
Â‡(QVXUHWKDWWKHWUDFNOD\RXWUHP DLQVFRQVLVWHQWIRUEDVHOLQHD QGVXEVHTXHQWPLQXWHZDON
WHVWV7KHWUDFNVKRXOGEH DVWUDLJKWFRUULGRU
7KHWUDFNVKRXOGEHIODWZLW KQRVWHSVEOLQGWXUQVRUREVWDF OHV
7KHPLQLPXPUHFRPPHQGHGOHQJWKIRUWKHWUDFNLVPHWHUV$ PHWHUOHQJWKLV
SUHIHUUHG
$PHDVXULQJWDSHVKRXOGEHXVHGW RPHDVXUHZDONLQJGLVWDQFH7K HWUDFNVKRXOGEH
PDUNHGHYHU\PHWHUV
7KHVDPHORFDWLRQVKRXOGEHXVHGDWHDFKYLVLWIRUDJLYHQSDWL HQW
7KLVVKRXOGEHDQDUHDLQZKLFKDFFHVVE\RWKHUSHRSOHFDQEHU HVWULFWHGGXULQJWKHWHVW
Â‡,QVWUXFWWKHSDWLHQWWRGUHVVFR PI[INVESTIGATOR_100225]\ZHDUDSSURSULDWHIRR WZHDUDQGWRDYRLGHDWLQJIRU
DWOHDVWKRXUVEHIRUHWKHWHV WZKHUHSRVVLEOHRUDSSURSULDWH 
Â‡$Q\SUHVFULEHGLQKDOHGEURQFKRGL ODWRUPHGLFDWLRQVKRXOGEHWDNH QKRXUEHIRUHWHVWRUZKHQ
WKHSDWLHQWDUULYHVIRUWHVW
Â‡7KHSDWLHQWVKRXOGUHVWIRUDWO HDVWPLQXWHVEHIRUHEHJLQQLQ JWKHPLQXWHZDONWHVWLQD
FKDLUQHDUWKHVWDUWLQJSRVLWLRQ
Â‡*LYHVWDQGDUGL]HGLQVWUXFWLRQVE HIRUHEHJLQQLQJWKHWHVWDVVS HFLILHGLQWKHVWXG\0LQXWH
:DON0DQXDO
Â³7KHREMHFWRIWKLVWHVWLVWRZ DONDVIDUDVSRVVLEOHIRUPL QXWHV<RXZLOOZDONEDFNDQG
IRUWKLQWKLVKDOOZD\6L[PLQXW HVLVDORQJWLPHWRZDONVR\ RXZLOOEHH[HUWLQJ\RXUVHOI
<RXZLOOSUREDEO\JHWRXWRIEUHDWKRUEHFRPHH[KDXVWHG<RXDU HSHUPLWWHGWRVORZGRZQ
WRVWRSDQGWRUHVWDVQHFHVVDU\ <RXPD\OHDQDJDLQVWWKHZDOO ZKLOHUHVWLQJEXWUHVXPH
ZDONLQJDVVRRQDV\RXDUHDEOH<RXZLOOEHZDONLQJEDFNDQGI RUWKDURXQGWKHFRQHV<RX
VKRXOGSLYRWEULVNO\DURXQGWKHF RQHVDQGFRQWLQXHEDFNWKHRWK HUZD\ZLWKRXWKHVLWDWLRQ
1RZ,Â¶PJRLQJWRVKRZ\RX3OHDVH ZDWFKWKHZD\,WXUQZLWKRXW KHVLWDWLRQÂ´
'HPRQVWUDWHE\ZDONLQJRQHODS\RXUVHOIÂ³$UH\RXUHDG\WRGRWKDW",DPJRL QJWRXVHWKLVZRUNVKHHWWR NHHSWUDFNRIWKHQXPEHURI
ODSV\RXFRPSOHWH,ZLOOFKHFN LWRIIHDFKWLPH\RXWXUQDURXQ GDWWKLVVWDUWLQJOLQHIW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 

&RQILGHQWLDO 3DJHRI5HPHPEHUWKHREMHFWLVWRZDON$6 )$5$63266,%/(IRUPLQXWHV EXWGRQÂ¶WUXQRUMRJ
6WDUWQRZRUZKHQHYHU\RXDUHUHDG\Â´
Â‡*LYHVWDQGDUGL]HGYHUEDOHQFRXUDJ HPHQWGXULQJWKHWHVWLQDQH YHQWRQHRIYRLFH
$WPLQXWHÂ³<RXDUHGRLQJZ HOO<RXKDYHPLQXWHVWRJRÂ´
$WPLQXWHVÂ³.HHSXSWKH JRRGZRUN<RXKDYHPLQXWHVWRJR Â´
$WPLQXWHVÂ³<RXDUHGRLQJZHOO<RXDUHKDOIZD\GRQHÂ´
$WPLQXWHVÂ³.HHSXSWKH JRRGZRUN<RXKDYHRQO\PLQXWHVO HIWÂ´
$WPLQXWHVÂ³<RXDUHGRLQJZ HOO<RXKDYHRQO\PLQXWHWRJR Â´
:KHQWKHWLPHULVVHFRQGVIURPFRPSOHWLRQ Â³,QDPRPHQW,Â¶PJRLQJWRWHOO\RXWR
VWRS:KHQ,GRMXVWVWRSULJKWZKHUH\RXDUHDQG,ZLOOFRPH WR\RXÂ´
$WPLQXWHVÂ³6WRSÂ´IW-1973 Tablet (praliciguat)  Ironwood Pharmaceuticals, Inc. 
Clinical Trial Protocol: C1973-204 Amendment 3  27 June 2018 
7KHGDWDDQGLQIRUPDWLRQUHODWHGWRP\OLQHIXQFWLRQZKLFKKDV EHHQLQFOXGHG
ZLWKWKLVILOHDUHWUXWKIXODQGDFFXUDWH
6LJQDWXUH3DJHIRU99&/,1
Y$SSURYDO
$SSURYHU-XQ*07